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Abstract 
 
 
Atherosclerosis is the primary cause of coronary artery disease, one of the major 
causes of death in the western world. Proliferation of vascular smooth muscle 
cells and subsequent alteration of the vessel wall is one of the major events in 
atherosclerosis and restenosis.  
The aim of the study was to investigate a) tylophorine, a phenanthroindolizidine 
alkaloid, which was shown to inhibit tumor cell proliferation, with regard to its 
influence on cell proliferation, mitogenic signalling pathways and/or the cell cycle 
in primary rat aortic vascular smooth muscle cells (VSMC) and human umbilical 
vein smooth muscle cells (HUVSMC) and b) a plant extract of Peucedanum 
ostruthium on its anti-proliferative activity in VSMC and its active substance. 
In this study we show that tylophorine inhibits PDGF-induced proliferation of 
VSMCs in the G0/G1–phase of the cell cycle. Tylophorine does not affect the 
major early PDGF-triggered signalling events. We found, however, a fast down 
regulation of cyclin D1 below control levels in response to tylophorine. This 
decrease in cyclin D1 levels is not due to a transcriptional inhibition of the cyclin 
D1 gene since mRNA levels of cyclin D1 are unaffected. Further analyses reveal 
that cyclin D1 is down-regulated by proteasomal degradation. Consistent results 
were obtained for HUVSMC treated with tylophorine. Therefore, tylophorine has 
a unique action of inhibiting proliferating smooth muscle cells by enhancing the 
degradation of cyclin D1.  
Furthermore, the analysis of 7 major coumarin compounds, contained in the 
DCM-extract of Peucedanum ostruthium, revealed that ostruthin is the only 
active substance which inhibits the proliferation of VSMC. Thus, we identified 
the anti-proliferative principle of the Peucedanum ostruthium extract and 
uncovered a novel bioactivity for ostruthin. 
 
 
 
 
 
 
  
 
Zusammenfassung 
 
 
Atherosklerose ist die Hauptursache für die Erkrankung der Hernkranzgefäße, 
eine der bedeutenden Todesursachen in der westlichen Welt. Die Proliferation 
von glatten Gefäßmuskelzellen und die damit verbundene Gefäßveränderung 
sind die wichtigsten Vorgänge bei Atherosklerose und Restenose.  
Das Ziel der Studie war es a) Tylophorine, ein Phenanthroindolizidinalkaloid, das 
für seine Tumorzellproliferation hemmende Aktivität bekannt ist, im Hinblick 
auf seine Einflusse auf die Zellproliferation, mitogene Signalwege und/oder dem 
Zellzyklus von primären Gefäßmuskelzellen der Ratte (VSMC), sowie glatten 
Gefäßmuskelzellen der menschlichen Nabelschnurvene (HUVSMC), zu 
untersuchen. Weiterhin sollte b) ein Pflanzenextrakt von Peucedanum 
ostruthium auf seine antiproliferative Wirkung an glatten Gefäßmuskelzellen 
(VSMC) analysiert, sowie die für seine Aktivität verantwortliche Substanz 
bestimmt werden.  
In dieser Studie zeigen wir, dass Tylophorine die PDGF-induzierte Proliferation 
von VSMC in der G1-Phase des Zellzyklus hemmt. Dabei werden die wichtigsten, 
von PDGF-induzierten Signalwege durch Tylophorine nicht beeinflusst. 
Weiterhin fanden wir heraus, dass Tylophorine den Cyclin D1 - Gehalt der Zelle 
schnell herunterreguliert.  Die Abnahme der Cyclin D1 Level wird nicht durch 
transkriptionelle Hemmung erreicht, da die mRNA-Level von Cyclin D1 
unbeeinflusst bleiben. Weitere Analysen ergaben, dass die Herunterregulierung 
von Cyclin D1 durch proteasomalen Abbau bedingt ist. Damit übereinstimmende 
Ergebnisse konnten auch für Tylophorine behandelte HUVSMC erzielt werden. 
Daher besitzt Tylophorine einen einzigartigen Wirkungsmechanismus, um 
proliferierende glatte Gefäßmuskelzellen zu hemmen, der sich durch einen 
schnellen proteasomalen Abbau von Cyclin D1 auszeichnet.  
Weiterhin ergab die Analyse der 7 wichtigsten, der Klasse der Coumarine 
zugehörigen Inhaltsstoffe des DCM-Extrakt von Peucedanum ostruthium,  
lediglich eine auf VSMC antiproliferativ wirksame Substanz – Ostruthin. Wir 
haben also das antiproliferative Prinzip des Peucedanum ostruthium Extrakts 
herausgefunden und eine neue Bioaktivität für Ostruthin gefunden. 
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2. INTRODUCTION  
 
2.1. Atherosclerosis   
 
2.1.1. Pathology of atherosclerosis   
 
Cardiovascular disease (CVD) is the leading mortal disease worldwide in the 
developed societies (Murray CJ et al., 1997). The combination of an unhealthy 
life-style, genetic susceptibility and increased lifespan is the common bases for 
atherosclerosis (Lusis AJ et al., 2000).  
Under normal physiological conditions the endothelium is a selective 
permeable barrier between blood and tissues. The important physical force 
acting on endothelial cells (EC) is fluid shear stress, which is able to change 
EC morphology. In the tubular regions of arteries, where the blood flow is 
laminar, EC are ellipsoid in shape and aligned in the direction of blood flow. In 
areas where flow is disturbed and oscillatory, for example in arterial branching 
or curvature, EC have polygonal shapes and no particular orientation. These 
regions have an increased permeability to macromolecules such as low-density 
lipoproteins (LDL) as well as platelets and blood monocytes and are 
preferential sites for lesion formation (Gimbrone MA et al., 1999).  
Accumulation of LDL in the sub-endothelial matrix is the initiating event in 
atherosclerosis development followed by modification of LDL via oxidation to 
produce oxLDL. Only this oxidized LDL is rapidly taken up by macrophages to 
generate so called foam cells - cholesterol-filled macrophages, which are found 
in early lesions of atherosclerosis (Glass CK and Witztum JL, 2001).  
Activated leukocytes produce a plethora of inflammatory mediators which 
promote vascular smooth muscle cells (VSMC) proliferation and migration 
(Ross R et al., 1999; Rivard A and Andre´s V et al., 2000; Dzau et al. 2002). 
Upon enrichment of lipid-rich necrotic debris and migration of VSMC from the 
medial layer of the artery, the lesion is advancing to ―fatty streaks‖ (Navab et 
al., 1996; Steinberg and Witztum, 1999). Further, accumulation of VSMC and 
VSMC-derived extracellular matrix consisting of a growing mass of 
extracellular lipid, mostly cholesterol and its ester, generates a fibrous plaque. 
  Introduction 
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Rupture or erosion of the lesion leads to thrombus formation resulting in 
myocardial infarction or stroke. Figure 1 depicts the initiation and progression 
of atherosclerosis.  
 
 
 
2.1.2. The role of VSMC in atherosclerosis  
 
In the vasculature, VSMC can be found in two different shapes – the 
―contractile‖ and the ―synthetic‖. Intimal SMCs differ significantly from medial 
SMCs and have unique atherogenic properties essential for the initiation of 
plaques (Mosse PR et al., 1985). Human medial SMCs express proteins 
involved in the contractile function of the cell, whereas those SMCs found in 
the intima have a higher proliferative index, and a greater synthetic capacity 
for extracellular matrix, cytokines and proteases (Campbell, 1994; Worth NF 
2001). Furthermore, SMCs can switch between the ―contractile‖ and 
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―synthetic‖ phenotype in response to atherogenic stimuli including cytokines 
(Corjay MH et al., 1989; Hautmann MB et al., 1997; Li X et al., 1997), 
extracellular matrix (Hedin U et al., 1998; Thyberg J et al., 1989), lipids 
(Pidkovka NA et al., 2007), shear stress (Reusch P et al., 1996), and reactive 
oxygen species (Su B et al., 2001). This ―phenotypic switching‖ facilitates many 
of the pathogenic roles of SMCs due to changes in SMC functions. SMCs of the 
―synthetic‖ phenotype migrate and proliferate more promptly than 
―contractile‖ SMCs and synthesize up to 25 to 46 times more collagen (Marra 
DE et al., 2000; Dzau VJ et al., 2002). 
Mechanism relevant for cell proliferation and migration are also involved in 
the growth of vascular obstructive lesions during restenosis post-angioplasty, 
graft atherosclerosis and transplant vasculopathy.  
 
 
2. Restenosis 
  
2.2.1. Pathology of restenosis   
 
Restenosis is the healing response of the arterial wall to mechanical injury. It 
consists of vessel remodeling and neointimal hyperplasia. The latter is 
characterized by smooth muscle migration/proliferation and extracellular 
matrix deposition.  
The arterial remodeling can be characterized as a continuous spectrum of 
changes in vascular dimension (Schwartz et al, 1998). For example, lumen 
deterioration in nonstented coronary arteries can lead to negative remodeling 
(vessel shrinkage) (Di Mario C et al., 1995; Mintz G et al., 1996). Here, 
adventitial myofibroblasts may play an important role. They are capable of 
collagen synthesis and tissue contraction (Staab ME et al., 1997; Labinaz M et 
al., 1997).  A protective effect might occur through the association between 
enhanced inflammation and vessel enlargement (Costa MA et al., 2001). 
But remodeling does not occur after stenting (Dussaillant G et al., 1995; Costa 
MA et al., 2000). Bare-metal stents prevent vessel shrinkage (elastic recoil and 
negative remodeling). The vessel narrowing occurs due to induction of an 
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enhanced neointimal hyperplasia response. This enhanced proliferative 
response has been the focus of pharmacological prevention of restenosis and 
led to the development of drug eluting stents (DES). 
 
 
2.2.2. The role of VSMC in restenosis 
 
Atherosclerotic stenosis necessitates arterial reconstruction procedures, 
including percutaneous transluminal coronary (balloon) angioplasty (PTCA), 
coronary artery bypass (Zargham R et al., 2008) and stenting. After the 
surgical treatments with or without stenting, restenosis occurs. VSMC play a 
vital role in this process. 
Whereas in healthy vessels VSMC are in a differentiated resting state, they 
dedifferentiate to the ‗synthetic‘ phenotype after encountering distinct 
cytokines or growth factors such as PDGF. 
PTCA, coronary artery bypass and stenting lead to endothelial dysfunction and 
cause an inflammatory state of the vessel. This initiates the VSMC hyper-
proliferation and migration driven by chemotactic stimuli. These processes 
result in the formation of a neointima mainly composed of VSMC, which 
subsequently deposit huge amounts of extracellular matrix (Kraitzer A., 2008). 
These events are followed by accumulation of other cell types like 
myofibroblasts and smooth muscle progenitor cells (Zargham R et al., 2008) 
 
 
2.2.3. Surgical treatments of atherosclerotic stenosis  
 
Opening of obstructed coronary arteries is often treated by PTCA. But this 
method of revascularization is limited by thrombosis at the site of angioplasty 
and elastic recoil, as well as VSMC growth in response to the balloon-induced 
injury that results in neointimal formation (Cooper Woods T et al., 2004).  
Further, obstructed coronary arteries are routinely treated by operative 
myocardial revascularization - coronary artery bypass grafting (CABG). The 
success of this approach depends on the frequently used saphenous vein grafts 
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in CABG (Reisinger U et al., 2009) and the loss of patency due to thrombosis, 
and intimal hyperplasia leading to vein graft restenosis.  
 
 
2.2.4. Stenting 
 
The incidence of restenosis after PTCA, stenting and coronary artery bypass is 
highly independent of the used method (Zargham R et al., 2008). It occurs up 
to 20% after bypass surgery (Griffiths H, 2004) and up to 40% within 6 months 
after percutaneous transluminal angioplasty (Schillinger M et al., 2003). 
Stenting has not significantly improved the patency rate (Cheng S et al., 
2003). Drug eluting stents (DES), first approved already 2003 by the FDA, 
seemed to be promising in prevention of restenosis. But on the one hand not all 
patients are responsive to the drugs used as coating agents like rapamycin or 
taxol (Cooper Woods T, 2004) and on the other hand there might be an 
increased risk for thrombosis with these coating agents (Maisel WH et al., 
2007). Therefore restenosis still remains the major problem of any type of 
coronary interventions. 
 
 
2.2.5. Pharmacological inhibitors in drug eluting stents  
 
Stent applications are limited by the frequent occurrence of restenosis due to 
smooth muscle cell proliferation leading to neointimal hyperplasia and 
surgical lesion revascularization. Coated stents with drugs that target smooth 
muscle cell proliferation reduce in-stent restenosis.  
Rapamycin and numerous agents, including the antineoplastic drug taxol, 
inhibit VSMC proliferation and migration (Jayaraman T and Marks AR, 1993; 
Marx SO et al., 1995; Poon M et al., 1996; Gallo R et al., 1999).   
Rapamycin is a macrocyclic lactone, which has a major intracellular receptor -
the immunophilin FKBP12 (FK506 binding protein). The rapamycin-FKBP12 
complex binds to the mammalian target of rapamycin (mTOR) (Sabers CJ et 
al., 1999), blocks cell-cycle progression at the G1-to-S transition in VSMC 
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(Mita MM et al., 2003; Marx SO et al., 1995) by increase of the cyclin-
dependent kinase inhibitor p27Kip1 expression. The specific mechanism 
underlying this effect is however unclear. Rapamycin also has further cellular 
effects that might contribute to its ability to prevent restenosis. The inhibition 
of mTOR by rapamycin-FKBP12 leads to inhibition of phosphorylation of 
p70S6K and the initiation factor 4E (eIF-4E) binding protein, 4E-BP1 (Hidalgo 
M and Rowinsky EK, 2000; Burnett PE et al., 1998). These two pathways may 
contribute to the modulation of cellular proliferation, but the precise 
mechanism how rapamycin prevents restenosis remains to be determined 
(Rosner D et al., 2005). 
In several clinical studies it could be demonstrated that stents coated with 
rapamycin lead to a reduction of in-stent restenosis compared to bare metal 
stents (BMS) (Morice MC et al., 2002; Leon MB et al., 2003; Sousa JE et al., 
2003). Also several rapamycin analogues, like everolimus (Grube E et al., 
2004) zotarolimus (Fajadet J et al., 2006) or biolimus (Chevalier B et al., 2007) 
were effectively tested for the use in DES. But, these devices have the 
potential to increase inflammatory and thrombogenic responses and to 
associate also with the polymers used for the delivery of antirestenotic agents, 
which may have life-threatening consequences (Virmani R et al., 2002).  
 
Taxol, which is also used as coating agent in DES, stabilizes the microtubule 
assembly and inhibits thereby the proliferation of cells. Through this 
mechanism taxol induces its anti-restenotic effects (Schiff PB et al., 1979; 
Schiff PB and Horwitz SB, 1980). Microtubules are polymers assembled from 
tubulin dimers, which are in a dynamic equilibrium of assembly and 
disassembly, regulated according to cell-cycle phase. They are a component of 
the mitotic spindle apparatus and play a role in migration, cell shape 
maintenance and growth-factor signaling (Dugina VB et al., 1995; Rosette C et 
al., 1995; Rosania GR and Swanson JA, 1996). Taxol binds to the beta-tubulin 
subunit in the microtubule and promotes its polymerization. This shifts the 
equilibrium between microtubules and the tubulin dimers toward assembly. 
Bundles of disorganized microtubules are formed at all phases of the cell cycle 
and therefore preventing M-phase progression. This mechanism interrupts the 
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cell division (Schiff PB and Horwitz SB, 1980; Rowinsky EK et al., 1988; De 
Brabander M et al., 1981).  
In several clinical studies it could be demonstrated that taxol-eluting stents 
prevent of in-stent restenosis to a higher percentage than BMS (Columbo A, 
2002; Tanabe K et al., 2003). But, there is also a report with insignificant 
difference in restenosis rates between taxol-eluting stents and BMS (Lansky 
AJ et al., 2004).  
Novel approaches are needed to improve the safety and efficacy of DES. One of 
the main components that determines the performance of a stent is the active 
drug. Here, is a lot of space for further improvements and new candidate 
compound identification.  
 
 
2.3. VSMC migration 
 
In response to pathological stimuli, VSMC switch from the contractile to a 
proliferative and migratory phenotype. This switching is necessary under 
normal physiological conditions for wound healing and during development in 
order to allow the growth of new vessels. Under pathophysiological conditions, 
however, it contributes to atherosclerosis or restenosis (Lundberg MS and 
Crow MT, 1999).  
 
Receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs) 
regulate via multiple signaling pathways the actin cytoskeleton polymerization 
and depolimerization. Trimeric G proteins, small G proteins, lipid kinases, 
Calcium-dependent protein kinases, ROCK, and MAPKs are key signaling 
molecules (Abedi H and Zachary I, 1995; Bornfeldt KE et al., 1995).  
To migrate, VSMC extend lamellipodia via actin polymerization toward the 
stimulus. Then the trailing edge needs to detach by degradation of focal 
contacts. This action is followed by generation of force by myosin II in the cell 
body to move the cell forward. The therefore needed actin polymerization is 
coordinated by several actin-binding proteins, such as WAVE, WASP and the 
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actin-related protein 2/3 (ARP2/3) complex, which become activated by the 
small G proteins Rho, Rac, and Cdc42 (Gerthoffer WT, 2007).  
VSMC accomplish their migration along concentration gradients of soluble 
chemicals or matrix components through cell polarization, cytoskeletal, and 
focal contact remodeling and traction forces. 
 
 
 2.3.1. Migratory stimuli for VSMC 
 
A wide variety of growth factors and cytokines have been linked to VSMC 
migration. VSMC respond to soluble factors such as cytokines and move along 
a gradient of varying adhesiveness due to different components of the ECM 
like integrins (Gerthoffer WT, 2007). Also, physical factors like shear stress 
influence VSMC migration. The best studied and most potent chemoattractant 
for VSMC of these factors is PDGF-BB (Bornfeldt KE et al., 1994; Hughes AD 
et al., 1996).  
 
 
2.3.2. Signaling cascades in VSMC migration 
 
In response to different pro-migratory stimuli including PDGF-BB, Rac-1 and 
Cdc42 members of the p21 activated protein kinase (PAK) family are 
activated. The PAKs can stabilize or destabilize actin as well as microtubules 
and are essential for the formation of lamellipodia (Tien Y and Autieri M, 
2006). Furthermore, activation of Rac and cdc42 leads to nucleation and the 
formation of new actin filaments via the Wiskott–Aldrich syndrome protein 
(WASP) and WASP-family verprolin-homologous protein (WAVE) (Takenawa T 
and Suetsugu S, 2007).  Myosin II is activated by PAK or Calcium/calmodulin 
(CaM)–myosin light chain kinase (MLCK) (Webb DJ et al. 2002; Vicente-
Manzanares M et al., 2005). Nevertheless every increase in myoplasmic Ca2+ 
concentration will activate MLCK and myosin II. Ca2+ oscillations were 
observed during PDGF-stimulated cell migration (Scherberich A et al., 2000) 
and MLCK inhibitors block VSMC migration (Kishi H et al., 2000; Nakayama 
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M et al., 2005). Further, Ca2+-independent activation of myosin II can occur 
through activation of RhoA and ROCK.  
 
 
2.4. VSMC proliferation  
 
2.4.1. VSM cell cycle regulation 
 
Vascular proliferation contributes to cellular processes such as inflammation, 
matrix alterations as well as the pathophysiology of in-stent restenosis and 
vein bypass graft failure. A strategy for the treatment of these conditions is to 
inhibit VSMC proliferation by specific targeting of the cell cycle regulation of 
VSMC. 
 
2.4.2. Cell cycle phases 
 
When VSMC are stimulated with growth factors, they enter G1- from G0-
phase. In the gap phase 1 (G1-phase), the cell assembles the factors which are 
necessary for DNA replication. Only during this G0 to S interval, cell cycle 
progression depends on growth factors. In case cells become serum-starved 
during the S to G2/M-phase interval, they continue to cycle until the 
completion of mitosis. If they are not exposed to growth factors again they exit 
into the G0 state afterwards (Pardee AB, 1989). In S-phase the DNA synthesis 
occurs. After DNA replication is completed, the cells enter another gap phase 
(G2). In this phase the cell prepares for mitosis (M). Between G1 - S and G2 - 
M interphases restriction points ensure correct cell cycle progression (Elledge 
SJ, 1996). 
Each phase of the cell cycle is tightly controlled by many regulatory 
mechanisms. The regulatory proteins controlling the cell-cycle progression 
belong to the family of cyclins, cyclin dependent kinases (CDK), CDK 
inhibitors (CKI) and the tumor-suppressor gene products p53 and 
retinoblastoma protein (Dzau VJ et al., 2002).  
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2.4.3. Cyclins, CDK and CKI 
 
CDKs form holoenzymes with the regulatory cyclins and coordinate the 
different cell cycle phases (Koepp DM et al., 1997). The activity of the phase-
specific cyclin-CDK comlex is regulated by modifying the threonine and 
tyrosine phosphorylation status and up and down regulation of cyclin levels. 
This is necessary for specific and correct progression through the cell cycle. 
CDK are ubiquitously expressed throughout the cell cycle. Their activity is 
regulated by the limited expression of cyclins. Transition through the G1-
phase of the cell cycle requires increasing accumulation of cyclin D-CDK4 and 
cyclin E-CDK2 complexes (Sherr CJ, 1995). The subsequent G2-M-phase 
transition is regulated by cyclin A-CDK2 and cyclin B-CDK1 complexes 
(Fig. 2). Furthermore, the cell cycle progression is regulated by cyclin-
dependent kinase inhibitors (CKI). The family of CKI includes the CIP/KIP 
members p21Cip1, p27Kip1, and p57Kip2, which inhibit several CDK (Sherr 
CJ and Roberts JM, 1995 and 1999). These CKI bind to CDK and prevent their 
activation. Further, the cell cycle progression is modulated by transcription 
factors. Activation of p53 induces the expression of the CKI p21CIP1 and thus 
inhibits the activity of the G1 cyclin-CDK complexes, leading to a G1-phase 
arrest (Levine AJ, 1997). The transcription factors of the E2F family control 
the gene expression of proteins important for S-phase entry and cell cycle 
regulation (Sherr CJ, 1995). During quiescence, E2F members are in 
complexes with retinoblastoma protein (RB) and inactive. Mitogenic 
stimulation leads to hyperphosphorylation of the retinoblastoma protein by the 
cyclin D–CDK4 and cyclin E–CDK2 complexes and to dissociation from E2F. 
Then, E2F activates the expression of genes such as those encoding cyclins E, 
cyclin A and CDK1.  
 
Introduction    
 
26 
 
 
 
 
 
2.4.4. Important G1-phase regulators 
 
D type cyclins are known to be mitogenic sensors that pass on signals to the 
cell cycle machinery (Sherr CJ and Roberts JM, 1999). They will be presented 
together with the CKI p21 in the following chapter. 
 
 
2.4.4.1. Cyclin D1 
 
Cyclin D1 is expressed as a response to many mitogenic signals. Its expression 
forces the cell to pass from G0- to G1-phase and to start proliferation (Sherr 
CJ, 1995 and 1996). After mitogenic stimulation, the mRNA levels of cyclin D1 
and correspondingly also the cyclin D1 expression levels increase. Cyclin D1 
mRNA levels as well as cyclin D1 expression levels are highly regulated after 
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induction. As already stated before, cyclin D1 is the regulatory subunit of 
CDK4 or 6, and is necessary for the transition from the G1 to S phase by 
mediating the phosphorylation of RB, the gatekeeper of the G1 phase. As long 
as mitogenic stimulation is present the induction of cyclin D1 continues 
throughout the G1-phase of the cell cycle. For the transition to S phase, cyclin 
D1 is exported from the nucleus to the cytoplasm. This export is dependent on 
phosphorylation of cyclin D1 at threonine (Thr)-286 by glycogen synthase 
kinase-3 (GSK-3) and the nuclear exportin CRM1. Then, cyclin D1 is degraded 
via proteolysis by the 26S proteasome (Alt JR et al., 2000; Perez-Roger I et al., 
1999; Sherr CJ and Roberts JM, 1999; Diehl JA et al., 1997 and 1998). The 
mechanism of cyclin D1 degradation will be explained in section 2.5.5. 
 
 
2.4.4.2. p21 
 
The cyclin D-CDK complex contains additionally p21 (Zhang H et al., 1994) 
also known as Cip1, Sdi1, Cap20, and Waf1 (Harper JW et al., 1993; el-Deiry 
WS et al., 1993; Xiong Y et al., 1992; Gu Y et al., 1993; Noda A et al., 1994). 
p21 also associates with cyclin E-CDK2, cyclin A-CDK2, and cyclin B-CDK1 
complexes, and inhibits these CDK (Harper JW et al., 1993 and 1995). 
Association of p21 with cyclin D-CDK4/6 inhibits RB phosphorylation and 
induces cell cycle arrest in G1-phase. Furthermore, p21 is a target gene of the 
p53 tumor suppressor, and mediates p53-dependent cell cycle arrest in 
response to DNA damage (el-Deiry WS et al., 1993). Overall, p21 is a negative 
regulator that keeps cells in G0-phase (Li Y et al., 1994) or stops the cell cycle 
in G1-phase by association and inactivation of E2F (Afshari CA et al., 1996).  
However, p21 is not just a cyclin–CDK inhibitor; in a certain amount it is 
required for normal cell cycle progression. p21 stabilizes and promotes active 
cyclin-CDK complex formation in a dose-dependent manner (Philipp J et al., 
1999; LaBaer J et al., 1997; Besson A and Yong VW, 2000; Weiss RH et al., 
2000). 
During S phase, PCNA is necessary for the formation of the DNA replication 
complex and therefore interacts with DNA polymerase δ (polδ) (Prelich G and 
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Stillman B, 1988; Kelman Z, 1997). p21 is able to block the ability of PCNA to 
activate polδ by competing with polδ on the same binding site of PCNA, 
leading to a DNA replication block and intra-S-phase arrest (Oku T et al., 
1998; Li R et al., 1994; Waga S et al., 1994). 
 
 
2.4.5. Regulation of cyclin and CKI degradation 
 
Mitogen-initiated signals regulate the trafficking and the proteolysis of cyclin 
D1 (Diehl JA et al., 1997 and 1998). The phosphorylation site of cyclin D1, the 
specific threonine residue (Thr-286) located near its C-terminus, needs to be 
phosphorylated by Glycogen Synthase Kinase-3β (GSK-3β) for cyclin D1 
polyubiquitination and its nuclear export. The activity of GSK-3β is modulated 
by the Ras, PI-3K, Akt pathway (Klinghoffer RA et al., 1996; Rodriguez-
Viciana P et al., 1996; Franke TF et al., 1997). GSK-3β can be modulated by 
phosphorylation on serine 9 leading to decreased catalytic activity (Stambolic 
V and Woodgett JR, 1994). The modulation of cyclin D1 via this pathway is 
important for G1-phase progression. 
After polyubiquitination and nuclear export, cyclin D1 is degraded by the 26 S 
proteasome. For the specific recognition and further degradation of cyclin D1, 
ubiquitin-ligases are necessary (Guo Y et al., 2005). The ubiquitin-ligases 
involved in this process under normal physiological conditions are still 
unknown. At least, after DNA damage, recent publications show that there are 
several E3 ubiquitin-ligases involved in cyclin D1 degradation such as 
FBXO31 (Santra MK et al., 2009) or FBX4 (Jia L and Sun Y; 2009). 
p21 is targeted for proteasomal degradation during cell cycle by several E3 
ligases, including SCFSKP2,  CRL4(Cdt2) and APC/CCdc20 (Amador V et al., 
2007; Bornstein G et al., 2003; Kim Y et al., 2008; Wang W et al., 2005; Yu ZK 
et al., 2007). For degradation, p21 needs to be phosphorylated at S130 and gets 
afterwards ubiquitylated and further processed by the proteasome (Coulombe 
P et al., 2004). Furthermore, p21 is also degraded in an ubiquitin-independent 
manner (Sheaff RJ et al., 2000; Chen X et al., 2004), which is mediated by 
Mdm2 (Jin Y et al., 2003; Zhang Z et al., 2004). Therefore, p21 is degradated 
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by ubiquitin-dependent and -independent pathways, although the exact 
involved regulatory mechanisms are unknown. 
 
 
2.5. PDGF signaling 
 
Platelet-derived growth factors (PDGFs) are mitogens acting on many cell 
types like fibroblasts or smooth muscle cells. The family of PDGFs is composed 
of four different polypeptide chains, PDGF-A, PDGF-B, PDGF-C and PDGF-D, 
encoded by four different genes. These PDGF chains can assemble into five 
different dimeric isoforms - PDGF-AA, PDGFAB, PDGF-BB, PDGF-CC and 
PDGF-DD (Fredriksson L et al., 2004). PDGF-BB has been shown to be by far 
the most potent stimulus for VSMC migration and proliferation (Andrae J et 
al., 2008).  
All the PDGFs share a similar structure with a typical growth factor domain 
which is involved in dimerization of the two subunits, receptor binding and 
receptor activation. The growth factor domain has a length of around 100 
amino acid residues and is also called PDGF/VEGF homology domain. This 
structural motive is also found in the family of VEGF-related growth factors 
(Joukov V et al., 1997) in many different organisms (Duchek P et al., 2001; 
Yamazaki Y et al., 2003). Further, the PDGFs have an accessory amino acid 
sequence found in the N- or C-terminus. It is involved in the regulation of the 
biological properties of these factors. For example, PDGF-A and PDGF-B have 
sequences involved in the binding to the extracellular matrix (LaRochelle WJ 
et al., 1991; Östman A et al., 1991). The PDGFs and their receptors are usually 
expressed in different cell types. During embryonic development PDGF-A is 
produced by the epithelial cells and its PDGFR-α is expressed by mesenchymal 
cells (Orr-Urtreger A and Lonai P, 1992). PDGF-B and PDGFR-β are mainly 
expressed in the developing vasculature. PDGF-B is produced by endothelial 
cells, and PDGFR-β is expressed by pericytes and vascular smooth muscle cells 
(Hellström M et al. 1999). During murine embryogenesis, PDGF-C is expressed 
in many cell types, like cardiomyocytes and vascular smooth muscle cells (Aase 
K et al., 2002), PDGF-D in the metanephric mesenchyme and PDGF-B in 
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endothelial cells (Bergsten E et al., 2001). In human primary vascular cells, 
PDGF-C is found in coronary artery vascular smooth muscle cells and PDGF-D 
in umbilical vein cells (Uutela M et al. 2001).  
 
 
2.5.1. PDGF receptor activation  
 
The tyrosine kinase receptors of the PDGFs are activated by ligand-induced 
dimerization or oligomerization (Heldin CH et al., 1998). The PDGF isoforms 
have two receptor binding epitopes and bind two receptor molecules 
simultaneously (Fretto LJ et al. 1993; Herren B et al., 1993). But the receptors 
are able to bind different chains. Whereas the α-receptor binds both A- and B-
chains, the β-receptor binds only the B-chain with high affinity. Therefore, the 
different PDGF combinations activate different receptor dimers. PDGF-AA 
leads to αα-receptor dimerization, PDGF-AB to αα- or αβ-receptor dimers and 
PDGF-BB induces αα, αβ or ββ combinations (Bishayee S et al., 1989; Heldin 
CH et al., 1989; Seifert RA et al., 1989; Kanakaraj P et al., 1991). For vascular 
smooth muscle cells it is known that they do not possess PDGF-α-receptors 
(Inui H et al., 1993). The existence of the other possible dimers PDGF-AC or 
PDGF-AD cannot be excluded but have not been described so far in vitro or in 
vivo (Tallquist M and Kazlauskas A, 2004). 
The PDGF-induced receptor dimerization leads to conformational changes of 
the kinase domains. They approach each other and enable mutual 
phosphorylation on tyrosine residues. For the PDGFR-β receptor it is Y857 and 
for the PDGFR-α receptor it is Y849 (Kazlauskas A, 2008). This 
autophosphorylation leads to further activation of several kinase domains at 
the receptor which are able to phosphorylate several target proteins 
(Kazlauskas A, 2008).  
In general, interactions between components in the different signaling 
pathways are necessary for the intracellular transduction of signals. Specific 
domains, like Src homology 2 (SH2) domains and phosphotyrosine binding 
(PTB) domains exert this interaction by recognition of phosphorylated tyrosine 
residues. There are also other domains like SH3 domains recognizing proline-
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rich regions (PH) domains. Furthermore, PDZ domains recognize C-terminal 
valine residue (Pawson T and Scott JD, 1997). 
 
 
2.5.2. Early events in PDGF receptor signaling 
 
Signal transduction molecules like the Src family of tyrosine kinases, 
phosphatidylinositol 3P kinase (PI3K), Src kinase, phospholipase C-γ (PLC-γ), 
the tyrosine phosphatase SHP-2, GTPase activating protein (GAP) for Ras, 
signal transducers and activators of transcription (Stats) and several other 
molecules bind to different phosphorylation sites in the PDGF α- and β-
receptors. This binding of different SH2 domain molecules is specific 
(Songyang Z et al., 1993). 
 
 
2.5.3. Signaling cascades downstream of the PDGF receptor 
 
PDGF receptor activation leads to further recruitment and activation of the 
signaling molecules mentioned above. This in turn activates a complex 
network driving many different signaling cascades contributing to different 
cellular responses such as cell proliferation, motility and cell differentiation. 
Important signal transduction pathways belong to the Src, MAPK, PI3K and 
(Jak)/STAT pathway and will be discussed in the following: 
 
The Src family of tyrosine kinases is important in the mitogenic response to 
PDGF (Bromann PA et al., 2004; Twamley-Stein GM et al., 1993; Roche S et 
al., 1995). The Src tyrosine kinase activity is regulated by the phosphorylation 
status of Y416 and Y530. Src becomes activated by phosphorylation of Y416 
and dephosphorylation of Y530 (Bjorge JD et al., 2000). Further, PDGF-
induced and Src mediated DNA synthesis seems to be linked to the 
transcription factor c-Myc, which participates in G1-to S-phase transition 
(Barone MV and Courtneidge SA, 1995). The Src-mediated transcriptional 
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activation of c-Myc, includes the transcription factor STAT3 (Bowman T et al., 
2001) and the tumor suppressor p53 (Broome MA and Courtneidge SA, 2000). 
For the activation of the mitogens-activated protein kinase (MAPK)-pathways, 
the activation of Ras is essential. The PDGFR-β regulates the activation of Ras 
by direct or indirect binding of the Grb2/Sos1 complex which results in 
phosphorylation of the MAPK kinase kinase (MKKK), leading to MKK 
activation (MEK 1/2) (Avruch J et al., 1994), which in turn phosphorylates the 
MAPK extracellular signal-regulated kinases (Erk1/2). The serine/threonine 
kinases Erk1/2 translocate to the nucleus and activate the protein kinase p90 
ribosomal S6 kinase/(MAPK)-activated protein kinase-1a (Dalby KN et al., 
1998; Frödin M and Gammeltoft S, 1999). This activates immediate early 
genes relevant for the cell cycle (c-fos, c-myc and c-jun), followed by cell cycle 
progression and proliferation (Murphy LO and Blenis J, 2006; Murphy LO et 
al., 2004; Kortenjann M et al., 1994). Additionally to Erk1/2, there are several 
more MAPKs activated by PDGF through the MKKK pathway particularly the 
p38MAPKs and the c-Jun NH2-terminal kinases (JNKs). 
The major downstream effector of PI3K is the serine/threonine kinase Akt. 
PI3K is activated by recruitment to the PDGF-receptor via its regulatory 
subunit p85 and leads to PI(3,4,5)P3 production. The latter molecule serves as 
anchor and causes the translocation of Akt to the inner membrane, recruits 
PDK1 and PDK2, which  in turn phosphorylate Akt on T308 and S473 (Kandel 
ES and Hay N, 1999; Fresno Vara JA et al., 2004). Then, Akt is able to 
modulate functions of several proteins involved in the regulation of cell cycle 
progression and proliferation.  One substrate of Akt is the glycogen synthase 
kinase-3 (GSK-3), which inactivates proteins like c-Myc and cyclin D or leads 
to their degradation. Hence, Akt phosphorylates the CDK inhibitors p21Cip1 
and p27Kip1 and leads to repression of their inhibitory effects on cell cycle 
progression (Cantley LC, 2002). 
STAT3 belongs to the Janus kinase (Jak)/STAT pathway and can also be 
responsible for the induction of cell cycle progression and anti-apoptotic effects 
(Lim CP and Cao X, 1999). STAT3 can be activated by PDGF and plays an 
important role in the G1-/S-phase transition through the expression of the 
immediate early gene c-myc, the up regulation of cyclin D1, cyclin A and the 
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down regulation of CDK inhibitors p21Cip1 and p27Kip1 (Yu H and Jove R, 
2004; Hirano T et al., 2000). 
 
 
2.5.4. PDGF signaling in vascular disease 
 
During the development of atherosclerosis and restenosis, several cytokines 
and growth factors are important like tumor necrosis factor-α (TNF-α), 
interferon-γ (IFN-γ), PDGF, transforming growth factor-β (TGF-β) and insulin-
like growth factor-I (IGF-I) (Tedgui A and Mallat Z, 2006). But, as already 
mentioned above, PDGF-BB is the most potent stimulus for both, proliferation 
and migration of VSMC and extracellular matrix production (Andrae J et al., 
2008). This indicates an active role of PDGF in the tissue remodeling during 
the progression of atherosclerosis and restenosis. In addition, it was shown, at 
least in animal models, that the selective inhibition of PDGF-induced signaling 
cascades inhibits neointima formation (Dong LH et al., 2010). 
 
 
2.6. Investigated natural products and medicinal plants 
 
A promising strategy for the treatment of atherosclerosis and restenosis is to 
inhibit VSMC proliferation by targeting specific the cell cycle regulation of 
VSMC. For the identification of such cell cycle specific inhibitors, natural 
products represent a rich source. They could provide new promising lead 
structures acting by novel molecular mechanisms.  
 
 
2.6.1. Tylophora indica - source and traditional use 
 
Tylophora indica (Asclepiadaceae), also known as Tylophora asthmatica, is a 
perennial climbing plant native to the forests of eastern and southern India. 
As reviewed by Chemler SR in 2001, it was included as an official drug in the 
Bengal pharmacoepia of 1884. This indigenous medicinal plant was 
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traditionally used for the treatment of various ailments like asthma as well as 
bronchitis, rheumatism and dysentery. Investigations of the pharmacological 
properties have confirmed the anti-asthmatic effects of Tylophora indica leaf 
extracts (Shivpuri DN et al. 1972). Currently the Tylophora indica extract is 
marketed by several pharmaceutical companies as anti-asthmatic herbal drug. 
The plant contains several phenanthroindolizidine alkaloids (Gellert E., 1982).  
The major alkaloid is tylophorine and was first isolated from Tylophora indica 
in 1935. It has been reported to have anti-inflammatory (Gopalakrishnan C et 
al. 1979 and 1980), immunosuppressive (Ganguly T and Sainis KB, 2001) and 
anti-leukemic (Gellert E., 1982) properties. Further, an anti-tumor activity for 
tylophorine was published by Donaldson et al. in 1968.  
In addition, Tylophora indica contains several more structurally-related 
similar alkaloids, like tylophorinidine, (+)-septicine and (+)-isotylocrebrine. 
 
 
2.6.1.1. Chemical structure of tylophorine  
 
The structure including the stereochemistry of tylophorine was reported in 
1960 by Govindachari and colleagues. Tylophorine is a 2,3,6,7-
tetramethoxyphen-anthro-(9,10,6′,7′)-indolizidine alkaloid (Fig. 3). It was first 
reported to have the (S)-stereochemistry; later revision led to the (R) 
conformation (Buckley TF and Rapoport H, 1983). 
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2.6.1.2. Tylophorine and cancer 
 
As mentioned above, Tylophora alkaloids were known for its anti-leukemia 
properties since the 1960s. Tylocrebrine was tested in clinic trials in 1966 and 
failed due to central nervous system toxicity. Therefore, these alkaloids were 
not used for further anti-cancer drug development. Later, tylophorine was 
tested in animal models. (R)-Tylophorine was non-toxic in rats up to a dose of 
500 mg/kg (Gopalakrishnan C et al., 1979), and non-toxic in hamsters up to 60 
mg/kg (Bhutani KK et al., 1987). CNS toxicity has been observed in rats at 
high doses of (R)-tylophorine (Gopalakrishnan C et al., 1979). 
Tylophorine regained popularity again in the last decade. It was then used as 
the lead structure for the development of novel anti-proliferative analogs 
effective against several cancer cell lines (Staerk D et al., 2002; Gao W et al., 
2004). Tylophorine ((+)-S-tylophorine) exerts potent growth-inhibitory effects 
on HepG2, a human hepatocellular carcinoma cell line, and KB, a human 
nasopharyngeal carcinoma cell line. The tylophorine analogs exhibit potent 
cytotoxic activity against a broad range of human cancer cells, like A549 (lung 
cancer cell line), ZR-751 (breast cancer cell line), DU-145 (prostate cancer cell 
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line), KB (nasopharyngeal cancer cell line), and KB-Vin (multidrug resistant 
KB subline) (Wei L et al., 2007). 
 
 
2.6.1.3. Tylophorine analogues and their possible mechanism of action 
 
For tylophorine, especially the (+)-S-tylophorine, there are already several 
investigations performed on cancer cell lines. (+)-S-tylophorine significantly 
inhibits activator protein-1, cAMP response element and nuclear factor κB 
(NF-κB) mediated transcription (Gao W et al., 2004). Furthermore, tylophorine 
is able to arrest HepG2, HONE-1 (epithelial tumor cell line), and NUGC-3 
(stomach cancer cells) carcinoma cells in G1-phase of the cell cycle by down 
regulation of cyclin A2 expression (Wu CM et al., 2009). However, the exact 
mechanism of action of tylophorine is still unknown. 
 
 
 
2.6.2. Peucedanum ostruthium  
 
2.6.2.1. Traditional use 
 
Extracts from plants traditionally used against inflammatory indications were 
tested on their ability to inhibit VSMC proliferation. In the frame of this 
ongoing screening, done in big part by the diploma student Thomas Nakel, a 
highly active hit was found, the DCM-extract from Peucedanum ostruthium 
rhizomes.  
 
2.6.2.2. Source  
 
Peucedanum species have a long history of usage in the Austrian traditional 
medicine. Especially the rhizomes of Peucedanum ostruthium have been 
traditionally used for inflammatory diseases since ancient times. Furthermore, 
anti-inflammatory action of Peucedanum ostruthium root extract has recently 
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been demonstrated in vivo upon oral administration to rats that were 
subjected to carrageenan-induced paw edema (Hiermann A and Schantl D, 
1998).   
 
 
2.7. Aims of the study 
 
Cardiovascular disease (CVD) is the leading mortal disease worldwide in the 
developed societies (Murray CJ et al., Lancet, 1997). Proliferation of vascular 
smooth muscle cells (VSMC) contributes to atherosclerosis and restenosis. For 
the VSMC-mediated vessel narrowing processes, mitogen-induced cell division 
is essential and PDGF-BB is one the most important mitogenic factors to 
induce VSMC proliferation. 
Natural products are often a rich source for the identification of new lead 
structures and novel molecular mechanisms. Consequently we selected a 
compound which already demonstrated a promising activity profile in cancer 
cells – tylophorine.  
We examined if tylophorine (I) possesses anti-proliferative activity in rat and 
human smooth muscle cells, (II) interferes with key cell cycle regulatory 
proteins and (III) further aimed to confirm the discovered effects in human 
saphenous veins in culture. The unique activity that we observed suggests 
tylophorine as a promising lead for the development of pharmaceuticals 
targeting vasculo-proliferative disorders, such as restenosis or atherosclerosis.  
Further, we examined a plant extract from the roots of Peucedanum 
ostruthium, a traditionally used medicinal plant with anti-inflammatory 
properties, for a putative anti-proliferative activity in rat aortic VSMC. 
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3. Materials and methods 
3.1. Materials 
 
3.1.1. Chemicals 
 
All chemicals were obtained from Sigma Aldrich (St. Louis, MO, USA), Fluka 
(Buchs, Switzerland) or Carl Roth (Karlsruhe, Germany) unless otherwise 
stated.  
Tylophorine was initially provided by Prof. Proksch (University of Duesseldorf, 
Department of Pharmaceutical Biology), but for further studies bought from 
Alexis Biochemicals (Switzerland).  
 
 
3.1.2. Buffers and solutions 
 
Blotting buffer 5 X  
TRIS-base 15.17 g 
Glycine 72.9 g 
dH2O ad 1000 ml  
 
Complete™ 25 X 
(Roche Diagnostics, Penzberg, Germany) 
one tablet 
dH2O 2 ml 
 
Coumaric acid (stock solution)  
p-Coumaric acid 0.15 g 
DMSO ad 10 ml 
 
Crystal violet solution  
Crystal violet 0.5 % (m/v)  
in 20 % methanol  
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Digestion buffer  
Collagenase (246U/mg) 0.1 g 
HEPES 0.24 g 
Ascorbic acid 0.005 g 
Gentamicin sulphate 0.005 g 
BSA 0.1 g 
Ham´s F12 medium ad 100 ml  
 
ECL  
dH2O 4.5 ml 
TRIS-base, 1 M pH 8.5 0.5 ml 
Luminol (stock solution) 25 μl 
p-Coumaric acid (stock solution) 11 μl 
H2O2 (30 %) 3.0 μl 
 
Electrophoresis buffer 5 X  
TRIS-base 15.0 g 
Glycine 72.0 g 
SDS 5.0 g 
Aqua dest. ad 1000 ml  
 
Ethanol/sodium citrate solution 
Sodium citrate 0.1 M 50 % (v/v)  
in ethanol 
 
FACS buffer pH 7.37  
NaCl 8.12 g 
KH2PO4 0.26 g 
Na2HPO4 2.35 g 
KCl 0.28 g 
LiCl 0.43 g 
NaN3 0.20 g 
Na2EDTA  0.36 g 
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dH2O ad 1000 ml  
 
HBS buffer pH 7.05 
NaCl  280 mM 
KCl 10 mM 
Na2HPO4·2H2O 1.5 mM 
Dextrose 12 mM 
HEPES 50 mM 
adjust to pH 7.05 
 
HBSS buffer pH 7.4  
NaCl 8.18 mg 
KCl 400 mg 
Na2HPO4 19.75 mg 
KH2PO4 50 mg 
CaCl2 x 2 H2O 180 mg 
MgSO4 97.5 mg 
Glucose 1000 mg 
HEPES 4760 mg 
dH2O ad 1000 ml  
 
HFS-buffer  (Hypotonic fluorochrome solution)  
Sodium citrate 0.1 % (w/v) 
Triton X-100 (in PBS) 0.1 % (v/v) 
 
Luminol (stock solution)  
Luminol 0.44 g 
DMSO ad 10 ml 
 
Lysis buffer (stock solution)  
HEPES 50 mM 
NaCl 50 mM 
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NaF 50 mM 
Na4P2O7 x 10 H2O 10mM 
EDTA 5 mM 
Na3VO4 1 mM 
 in dH2O 
The reagents were dissolved in 325 ml H2O (4°C), adjusted to pH 7.5 
with NaOH and filled up to a final volume of 430 ml. 
 
PBS pH 7.4  
NaCl 7.2 g 
Na2HPO4 1.48 g 
KH2PO4 0.43 g 
dH2O ad 1000 ml  
 
PMSF 
PMSF (in isopropanol)  0.1 M  
 
Resolving gel 10 %  
PAA solution 30 %  5 ml 
TRIS-base pH 8.0 3.75 ml 
SDS 10 % 0.15 ml 
dH2O 6.1 ml 
TEMED 15 μl 
APS 10 % 75 μl 
 
Sample buffer for RNA gel (10 X) 
Bromphenol blue  4.0 mg 
dH2O  5.0 ml 
Glycerol  5.0 ml 
 
SDS sample buffer (stock solution) 
TRIS-HCl solution, 0.5 M pH 6.8 37.5 ml 
SDS 6.0 g 
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Glycerol 30.0 ml 
Bromophenol blue 15.0 mg 
dH2O ad 1000 ml  
 
Stacking gel  
PAA solution 30 %  0.64 ml 
TRIS-HCl pH 6.8 0.375 ml 
SDS 10 % 37.5 μl 
Aqua dest 2.62 ml 
TEMED 7.5 μl 
APS 10 % 37.5 μl 
 
TBE (10 X) 
Tris base  108 g 
Boric acid 55 g 
EDTA 0.5 M pH 8.0  40 ml 
dH2O ad 1000 ml 
 
TBS-T pH 8.0  
TRIS-base 3.0 g 
NaCl 11.1 g 
Tween-20 (add after adjusting pH) 1 ml 
dH2O ad 1000 ml  
 
Trypsin/EDTA in PBS 
Trypsin 0.05 % 
EDTA 0.02 % 
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3.1.3. Cell culture media and reagents 
 
Calf serum  Lonza Group Ltd. (Basel, Switzerland) 
Complete protease inhibitor  Roche Diagnostics (Basel, Switzerland)  
Collagenase II  Invitrogen (Carlsbad, CA, USA)  
DMSO   Fluka (Buchs, Switzerland)  
Dulbecco´s Modified Eagle Medium (DMEM)  
4.5 g/L glucose, w/o L-glutamine  Lonza Group Ltd. (Basel, Switzerland)  
Ham's F-12 medium  Invitrogen (Carlsbad, CA, USA) 
L-glutamine 200 mM  Lonza Group Ltd. (Basel, Switzerland)  
Penicillin/streptomycin mixture  
(10,000 U/ml potassium penicillin/ 
10,000 μg/ml streptomycin sulphate)  Lonza Group Ltd. (Basel, Switzerland) 
Recombinant human PDGF-BB  Bachem (Weil am Rhein, Germany) 
Trypsin (1:250)  Invitrogen (Carlsbad, CA, USA)  
 
Growth medium  
DMEM 500 ml 
Calf Serum (CS) 10 % 
Penicillin/Streptomycin 100 U/ml/100 μg/ml 
L-glutamine 2 mM 
 
Starving medium  
DMEM 500 ml 
Calf Serum (CS) 0.1 % 
Penicillin/Streptomycin 100 U/ml/100 μg/ml 
L-glutamine 2 mM 
 
Freeze medium  
DMEM 8.0 ml 
Calf Serum (CS) 2.0 ml 
DMSO 1.1 ml 
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Primary Antibodies 
Target  Source  Dilution     Provider 
ACTIVE-JNK®  rabbit pc 1:1000 Promega (Madison, USA) 
α-smooth muscle-  
actin-FITC  mouse  mc 1:250 Sigma Aldrich (St. Louis, USA) 
α-tubulin  mouse  mc 1:1000  Santa Cruz (Santa Cruz, USA) 
c-Myc rabbit pc 1:1000  New England Biolabs (Beverly, USA) 
Cyclin D1  mouse mc 1:1000 New England Biolabs (Beverly, USA) 
Retinoblastoma protein-  
S807/811  rabbit  pc 1:1000  New England Biolabs (Beverly, USA) 
phospho Akt S473  rabbit pc 1:1000  New England Biolabs (Beverly, USA) 
phospho Erk1/2 Y202/204 rabbit  pc 1:1000  New England Biolabs (Beverly, USA) 
phospho p38 Y180/182 rabbit pc 1:1000  New England Biolabs (Beverly, USA) 
phospho STAT3 Y705 rabbit  pc 1:1000  New England Biolabs (Beverly, USA) 
 
Secondary, HRP-linked antibodies 
mouse IgG  goat  1:2500  Upstate (Charlottesville, USA) 
rabbit IgG  goat  1:2500  New England Biolabs (Beverly, USA) 
Antibodies were diluted as stated above in TBS-T and prepared with 5 % BSA 
or 5 % milk powder. 
 
Used kits 
Cell Proliferation ELISA,  
BrdU (chemiluminescent)  Roche Diagnostics GmbH (Basel, Switzerland)  
FITC BrdU Flow Kit  BD Biosciences Pharmingen (San Diego, USA) 
 
 
Miscellaneous material 
96-well Microplates  Greiner bio-one (Frickenhausen, Germany)  
Cell scraper  Greiner bio-one (Frickenhausen, Germany) 
Gel blotting paper  Whatman plc (Kent, UK) 
Precision Plus Protein™ Standard  BIO-RAD Laboratories (Hercules, CA, USA) 
Materials and methods    
 
46 
 
PVDF Membrane (0.2 μm)  BIO-RAD Laboratories (Hercules, CA, USA) 
Serological Pipettes   Sarstedt GmbH (Nümbrecht, Germany)  
Tissue Culture Dishes (6 cm, 10 cm)  Greiner bio-one (Frickenhausen, Germany) 
Tissue Culture Flask 75 cm2  Sarstedt GmbH (Nümbrecht, Germany)  
 
 
3.1.4. Technical equipment 
Digital SLR Camera E-330  Olympus Europa GmbH (Hamburg, Germany) 
FACSCalibur™ BD Biosciences Pharmingen (San Diego, CA, USA) 
Fluorescence Microscope BX51 Olympus Europa GmbH (Hamburg, Germany) 
Galaxy Mini Microcentrifuge  VWR International Inc. (West Chester, PA, USA)  
HERAcell™ 150 Incubator  Thermo Fisher Scientific Inc. (Waltham, CA, USA)  
Heraeus™ B15 Incubator  Thermo Fisher Scientific Inc. (Waltham, CA, USA)  
Heraeus™ Fresco™ Centrifuge  Thermo Fisher Scientific Inc. (Waltham, USA) 
HERAsafe™ KS Workbench  Thermo Fisher Scientific Inc. (Waltham, USA)  
LAS-3000™ Luminescent Image Analyzer  Fujifilm (Tokyo, Japan) 
Light Microscope CKX31  Olympus Europa GmbH (Hamburg, Germany) 
Mini-PROTEAN™ 3 Cell  BIO-RAD Laboratories (Hercules, USA) 
Mini Trans-Blot™ BIO-RAD Laboratories (Hercules, USA) 
Power Pac™ HC power supply BIO-RAD Laboratories (Hercules, USA)  
Power supply Power Pac™ HC  BIO-RAD Laboratories (Hercules, USA) 
RCT basic Magnetic Stirrer  IKA™ Laboratory equipment (Staufen, Germany)  
Tecan GENios™ Pro  Tecan Sunrise™ Tecan (Mannedorf, Switzerland) 
Vibrax VXR basic Shaker  IKA™ Laboratory equipment (Staufen, Germany)  
Vi-Cell™ XR Cell Viability Analyzer  Beckman Coulter (Fullerton, USA) 
Vortex Shaker  VWR International Inc. (West Chester, USA)  
 
3.1.5. Software 
AIDA™ version 4.06  Raytest GmbH (Straubenhardt, Germany) 
Image Reader LAS-3000™  Version 2.0 Fujifilm (Tokyo, Japan) 
Vi-Cell™ XR 2.03  Beckman Coulter (Fullerton, USA) 
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3.2. Methods 
 
3.2.1. Cell culture 
 
3.2.1.1. Vascular Smooth Muscle Cell Isolation and Cultivation 
 
Vascular smooth muscle cells (VSMC) from thoracic aortas of Sprague-Dawley 
rats were kindly provided by Kathy K. Griendling (Emory University, Atlanta, 
USA). These cells were used in all experiments elaborating rat aortic VSMC.  
Human umbilical vein smooth muscle cells (HUVSMC) were kindly provided 
by David Bernhard (Allgemeines Krankenhaus, Vienna, Austria).  
 
 
3.2.1.1.1. Isolation 
 
Besides the provided VSMC from KK Griendling, further VSMC were isolated 
from thoracic aortas of Fischer rats to learn the isolation procedure. The 
method was done as follows: 
The aortas were cut out from rats and placed in PBS, cleaned from connective 
tissue and then cut longitudinally. After that the aortas were incubated for 15 
min at 37 °C in digestion buffer (Ham's F-12 medium supplemented with 253 
U/ml collagenase II, 10 mM HEPES, 0.28 mM ascorbic acid, and 0.1% bovine 
serum albumin). The adventitia and the endothelium were scrapped off and 
the aortas were dissected, followed by a second incubation in digestion buffer 
at 37 °C for 3 h to complete the enzymatic digestion. Hereupon the cells were 
harvested by centrifugation (10 min, 1100 rpm, 25°C) and then seeded with 
growth medium (Dulbecco's modified Eagle's medium supplemented with 2 
mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% calf 
serum) in a 25 cm2 flask. To verify the cells as VSMC they were incubated with 
a monoclonal anti-α-smooth muscle actin FITC-conjugated antibody (1:250 
dilution, Sigma) and analyzed by fluorescence microscopy. 
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3.2.1.1.2. Cultivation of VSMC 
 
VSMC were grown at 37 °C and 5 % CO2 in DMEM containing 2 mM 
glutamine, 100 U/ml penicillin/100 μg/ml streptomycin and 10% calf serum. 
Cells were passaged every 3 to 5 days. Cells of passages 5 to 15 were used for 
the experiments. For splitting, the growth medium was removed and cells 
were washed once with PBS, before incubation with 3 ml (per 75 cm2 flask) 
trypsin/EDTA for around 2 min. Trypsin-reaction was stopped with 7 ml of 
10% CS containing DMEM, followed by centrifugation for 4 min at 1,250 rpm. 
1.5 x 106 cells were seeded per 75 cm2 flask. Basic cell parameters were 
routinely checked using a cell viability analyzer (ViCell™, Beckman Coulter, 
USA). 
 
3.2.1.1.3. Storage 
 
For rat aortic VSMC it is possible to freeze and thaw the cells without 
significant loss of viability. 
Freezing of VSMC was done by harvesting through trypsinization, followed by 
centrifugation and resuspension in ice-cold freezing medium (containing 10% 
DMSO). Approximately 1 x 106 cells/ml suspension was frozen in cryo-vials. 
First cells were incubated at -20 °C for one day, then at -80 °C for three days 
before they were long-term stored in liquid nitrogen at -196 °C.  
Thawing of the cells was done by warming the cryo-vials to 37 °C and 
immediate suspension in warm 20 ml growth medium in 75 cm2 flasks. The 
growth medium was changed after 24 h.  
 
3.2.1.1.4. Smooth muscle alpha-actin staining 
 
The alpha-type actin is specific for vascular smooth muscle cells (Gabbiani et 
al., 1981). 
To verify the identity of the cells that we obtained, VSMC were seeded at a 
density of 2 x 105 cells/well on coverslips in 12-well plates. After 24 h they were 
washed once with ice-cold PBS and then fixed with 1 ml of 1:1 acetone/MeOH 
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for 5 min on ice. After that the cells were washed twice with ice-cold PBS. 
Coverslips were incubated with 20 μl of antibody solution (FITC-conjugated 
smooth muscle alpha-actin antibody diluted 1:250 in PBS containing 1% BSA) 
for 60 min on 4 °C at dark. Subsequently the coverslips were washed twice 
with PBS, fixed on a glass slide using mounting medium (Sigma Aldrich, MO, 
USA) before drying overnight in the dark. Cells were analyzed using a 
fluorescence microscope (Olympus BX51, Olympus Europe GmbH, Hamburg, 
Germany) and cell imaging software (cell^F software, Europe GmbH, 
Hamburg, Germany). 
 
 
3.2.2. SDS gel electrophoresis and western blot analysis. 
 
3.2.2.1. Whole cell protein lysate 
 
For cell lysate, cells were grown in 60 mm dishes to ~80% confluency and 
treated as described. Then cells were washed once with ice-cold PBS and lysed 
with freshly prepared lysis buffer (100 μl per 6 cm dish; for composition see 
3.1.2.) for 5 min on ice. Afterwards the cell debris was scraped off and lysate 
were cleared by centrifugation at 13,000 rpm for 10 min at 4 °C. 5 μl of the 
lysate was used for quantification of protein amount by the Bradford method 
(as described below). 90 μl of the supernatant were diluted 1:3 with 3 x SDS 
sample buffer (containing 15% 2-mercaptoethanol),  and then boiled for 5 min 
at 95 °C and stored at -20 °C. 
 
3.2.2.2. Protein quantification 
 
The amount of protein was determined using the Bradford method. This 
method uses the dye Coomassie Brilliant Blue G-250, whose absorbance 
maximum after binding to proteins is increased from 465 nm to 595 nm. The 
protein lysate was diluted in ddH2O 1:10. 10 μl were transferred into a 96-well 
plate. Every sample was measured in triplicate. As a calibration curve, 
different concentrations of BSA in water were used (50-500 μg/ml). 190 μl 
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diluted Bradford reagent (1:5 dilution in water, Roti® - Quant, Roth) was 
added to the standards and the samples. Afterwards the plate was incubated 
for 1 min and measured using a microplate absorbance reader at 595 nm 
(Tecan Sunrise™ microplate reader). Protein concentrations were calculated 
using the calibration curve.  
 
3.2.2.3. SDS-PAGE 
 
The protein separation was done according to Laemmli with a sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).  
Theses gels were prepared using a 30% solution of PAA/0.8% bisacrylamide 
and a Mini-PROTEAN™ 3 Cell System (BIO-RAD). The concentration of PAA 
in the resolving gel was 10% in all cases. The protein amount loaded on the gel 
was 25 μg for all targets and separated by electrophoresis (100 V for 21 min to 
stack proteins and at 200 V for 36 min to separate proteins). 
 
3.2.2.4. Western blotting and detection 
 
The blotting of the separated proteins on a PVDF membrane was done by a 
tank blotting technique. By applying 100 V for 90 min in a Mini Trans-Blot™ 
Electrophoretic Transfer Cell System (BIO-RAD) the proteins were 
transferred. Then membranes were blocked with 5 % fat-free milk powder in 1 
X TBS-T for at least 1 h and washed three times with 1 X TBS-T for 10 min, 
followed by incubation with specific antibodies at 4 °C overnight. The 
antibodies were diluted as stated above. After washing the membranes three 
times for 10 min with 1 X TBS-T they were incubated with the respective 
horseradish-peroxidase conjugated secondary antibodies for 2 h. Subsequently 
membranes were washed three times with 1 X TBS-T for 10 minutes and 
incubated with ECL-solution before visualization of the protein bands by 
detection with a LAS-3000™ (Fujifilm) luminescent image analyzer. The band 
intensity was specified by densitometric analysis using AIDA software 
(Raytest).  
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3.2.3. Flow cytometry 
 
Depending on the distribution of cells in the G0/G1-, S-, and G2/M-phase of the 
cell cycle the content of DNA varies and is characteristic for each phase. Cells 
in the G0/G1-phase have a diploid set of chromosomes and cells in G2/M-phase 
have a doubled one. The S-phase cells appear between G0/G1- and G2/M-
populations due to the progressive DNA-synthesis.  
To analyze the effect of tylophorine on cell cycle distribution flow cytometry 
(FACSCalibur, BD Biosciences) was used. It is a method to analyze individual 
cells suspended in a fluid to analyze cell cycle distribution, apoptosis or intra- 
or extracellular fluorescently labeled proteins. To determine cell cycle stages, 
apoptosis and DNA-synthesis in VSMC we used the below described methods. 
 
 
3.2.3.1. Propidium iodide staining  
 
The cell cycle distribution of VSMC and HUVSMC was determined after 
propidium iodide (PI) staining according to Riccardi and Nicoletti in 2006. PI, 
is capable of labeling DNA by stoichiometrically binding to nucleic acids. 
Therefore, the fluorescence emission is proportional to the DNA content of a 
cell and can be detected by flow cytometry with 562-588 nm filters.  
For the PI staining of PDGF-BB-stimulated cells, VSMCs were seeded into 12-
well plates (1 × 105 cells/well), serum-starved, pretreated with test compounds 
or vehicle (DMSO 0.1%) for 30 min, and subsequently stimulated with PDGF-
BB (20 ng/ml). After indicated time points, cells were trypsinized, fixed with 
ice-cold hypotonic fluorochrome solution buffer [0.1% (w/v), sodium citrate 
0.1% (v/v), and Triton X-100 in PBS] containing 50 μg/ml PI, and incubated for 
2 h at 4°C.  
For the PI staining of CS-stimulated cell, VSMC were seeded in 6-well plates 
(5 X 104 cells/well) and remained in 10% CS-containing DMEM. After 24 h 
VSMC were treated with test compounds or vehicle (DMSO 0.1%) for the 
indicated time, and subsequently trypsinized, fixed with ice-cold hypotonic 
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fluorochrome solution buffer containing 50 μg/ml PI, and incubated for 2 h at 
4°C. 
All experiments with HUVSMC were performed in the same way. Cells were 
analyzed by flow cytometry on a FACSCalibur (BD Biosciences, San Jose, CA) 
by using CellQuest™ Pro software. Experiments were done in triplicate.  
 
 
3.2.3.2. BrdU/7-AAD staining and flow cytometry 
 
In order to analyze the influence of a compound on the cell cycle machinery, 
cycling cells can be arrested for example in S-phase by aphidicolin, an inhibitor 
of DNA-polymerase alpha and delta.  
To analyze the effect of tylophorine on DNA-synthesis in the S-phase of the cell 
cycle, a two-colour flow cytometric analysis was used (FITC BrdU Flow Kit 
(BD Pharmingen, USA). Bromodeoxyuridine (BrdU) is an analogue of the DNA 
precursor thymidine and is incorporated into newly synthesized DNA by cells 
progressing through S-phase. The incorporated BrdU is stained with specific 
anti-BrdU fluorescent antibodies. The levels of cell-associated BrdU are then 
measured by flow cytometry. Furthermore, the BrdU staining is coupled with a 
7-amino-actinomycin D (7-AAD) staining, a dye binding to total DNA similar 
to propidium iodide. With this combination, the enumeration and 
characterization of cells that are actively synthesizing DNA and the 
simultaneous evaluation of cell cycle phase is possible. 
For the analysis of PDGF-BB-stimulated VSMCs, cells were seeded in a 6-well 
plate (1 x 105/well) and starved in 2 ml starving medium for 24 h. Then cells 
were stimulated for 4 h with PDGF-BB, treated with aphidicolin (1 μM) for 15 
h and then washed twice with PBS. After washing, 2 ml DMEM/well and 10 
μM BrdU each well were added as well as 2 μM of aphidicolin for negative 
control, 0.1% of DMSO for positive control and 1 μM tylophorine as test 
compound. After 2 h, 4 h, 6 h, 8 h samples were prepared for FACS analysis 
with BrdU Flow Kit and therefore double stained with BrdU and 7-amino-
actinomycin D (7-AAD). 
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Furthermore VSMC were analyzed without previous synchronization by 
mitogen starvation. Here VSMC were seeded in a 6-well plate (1 X 105/well). 
The next day cells were treated with 1 μM tylophorine for 30 min. Then 10 μM 
BrdU was added to each well. After 24 and/or 48 h of treatment samples were 
prepared for FACS analysis with BrdU Flow Kit and double stained with 7-
amino-actinomycin D (7-AAD). 
 
 
3.2.3.3. Annexin V-FITC staining 
 
In apoptotic cells, phosphatidylserine PS is translocated from the inner to the 
outer leaflet of the plasma membrane, exposing PS to the external 
environment, whereas in normal cells PS is located on the cytoplasmic side of 
the cell membrane. Annexin V has a high affinity for PS. To analyze if the 
compound induces apoptosis an Annexin V-FITC Apoptosis Detection Kit 
(abcam, Cambridge, USA) was elaborated.  
The method is shortly presented: 
VSMC were seeded in a 12-well plate (1 X 105 cells/well), starved in 2 ml 
DMEM for 24 h, then stimulated with PDGF-BB and treated with 1 µM 
tylophorine, 0.1% DMSO as negative or 1 mM H2O2 as positive control for 
24 h. Then cell were collected by centrifugation and resuspended in 500 µl of 
1 X Annexin V Binding Buffer. After that, 5 µl of Annexin V-FITC and/or 5 µl 
PI were added and cells were incubated for 5 min at room temperature in the 
dark. Then VSMC were analyzed for Annexin V-FITC binding by flow 
cytometry (excitation = 488 nm; emission = 530 nm) using FACSCalibur (BD 
Biosciences, San Jose, CA) with CellQuest™ Pro software. Experiments were 
done in three independent experiments.  
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3.2.3.4. Mitotracker green staining 
 
For the measurement of the total mitochondrial mass per cell a MitoTracker® 
Green FM (Molecular Probes (Invitrogen)) staining agent was elaborated.  
For the mitochondrial staining of CS stimulated cells, VSMC were seeded in 6-
well plates (2 x 104 cells/well), remained in 10 % CS containing DMEM. After 
24 h VSMC were treated with tylophorine or DMSO 0.1%  for the indicated 
time, and subsequently trypsinized, fixed with ice-cold hypotonic fluorochrome 
solution buffer containing 200 nM MitoTracker Green® and incubated for 2 h 
at 4°C. 
All experiments with HUVSMC were performed in the same way. Cells were 
analyzed by flow cytometry on a FACSCalibur (BD Biosciences, San Jose, CA) 
by using CellQuest™ Pro software. Experiments were done in triplicate.  
 
 
3.2.4. Proliferation assays  
 
3.2.4.1 Crystal violet staining 
 
The crystal violet staining assay is an easy and cost effective method and 
delivers useful hints about the anti-proliferative activity of a compound.  
Crystal violet binds to DNA and stains cell nuclei. The optical density is 
measured by absorbance at 595 nm. Results represent the overall biomass of 
cells in a well. 
In this assay VSMC were seeded into 96 well plates (2 x 104 cells/ well), serum-
starved for 24 h, pretreated with tylophorine or vehicle (DMSO 1%) for 30 min 
prior to stimulation with PDGF-BB (20 ng/ml). After 48 h cells were washed 
three times with PBS, immediately fixed and stained with crystal violet 
staining solution [0.5% (m/v) crystal violet in 20% MeOH] for 15 min at room 
temperature. Plates were washed with dH2O and dried. After that, the dye was 
resolved in ethanol/sodium citrate solution [50% (v/v) sodium citrate in 
ethanol]. The optical density was determined using a 96-well plate reader 
(TECAN SunriseTM, Mannedorf, Switzerland). 
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3.2.4.2. 5-Bromo-2′-deoxyuridine incorporation assay 
 
5-bromo-2′-deoxyuridine (BrdU) incorporation during S-phase of the cell cycle 
can be used as measurement of DNA synthesis. For this method a cell 
proliferation kit (Cell proliferation ELISA (Chemiluminscent) - Roche 
Diagnostics) was employed. VSMCs were seeded into black clear bottom 96-
well plates (1 × 104 cells/well), serum-starved for 24 h, pretreated with 
tylophorine/test compound or vehicle (DMSO 0.1%) for 30 min, and 
subsequently stimulated with PDGF-BB (20 ng/ml) or 10 % calf serum. After 
30 min, 10 μM BrdU was added, and cells were further cultivated for 20 h. 
Then, cells were fixed, washed and incubated with an enzyme-coupled anti-
BrdU antibody according to the manufacturer's instructions. To determine the 
relative light units a 96-well plate reader was used (Tecan GENios Pro; 
Männedorf, Switzerland). Three independent experiments were always 
performed.  
 
 
3.2.4.3. Resazurin conversion assay 
 
Viability of VSMC was assessed by Resazurin conversion. Resazurin measures 
the metabolic activity of living cells. Viable cells continuously convert 
resazurin to resorufin, increasing the overall fluorescence and colour of the 
media surrounding the cells. Therefore the fluorescence is directly proportional 
to the number of resazurin converting cells and can be taken as a first measure 
for their proliferative capacity. 
VSMC were seeded in transparent 96-well plates (1 × 104 cells/well), serum 
starved, pretreated with tylophorine or vehicle for 30 min and subsequently 
stimulated for 48 h with calf serum (10%). Then cells were washed with PBS 
and incubated in DMEM containing 10 µg/ml resazurin for 2 h. Samples were 
measured by monitoring the increase in fluorescence at a wavelength of 580 
nm using an excitation wavelength of 535 nm in a 96-well plate reader (Tecan 
GENios Pro; Tecan Group Ltd., Männedorf, Switzerland). 
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3.2.5. RNA isolation and real-time qPCR analysis 
 
3.2.5.1. RNA isolation 
 
For the RNA isolation 8 x 105 VSMC were grown in 6 cm dishes. Total RNA 
was isolated using peqGOLD total RNA Kit (PEQLAB Biotechnologie) 
according to the manufacturer‘s instructions. VSMC were lysed with 400 µl of 
lysis buffer, scraped from the dish and homogenized. DNA was removed by the 
supplied DNA removing columns. Then the samples were mixed with 70 % 
ethanol, shortly vortexed and applied to the RNA-binding columns. The bound 
RNA on the columns was washed three times and then dried by centrifugation 
at full speed (10,000 X g, 1 min). Afterwards RNA was eluted from the column 
in 50 μl RNase-free H2O and quickly frozen at -80 °C.  
The quality of the RNA was controlled on 1% -agarose gel [1.0 g agarose in 100 
ml 1 x TBE, SYBR Safe DNA gel stain 10,000 X conc. (Invitrogen, Carlsbad, 
USA)]. 9 μl of RNA solution was mixed with 1 μl 10x sample buffer. A peqGold 
1 kb DNA ladder (PEQLAB Biotechnologie) was used as control. Samples were 
separated at 120 V for 60 minutes using 0.5x TBE as running buffer. Bands 
were visualized by UV transillumination and scanned in a gel documentation 
system (Biostep). 
 
 
3.2.5.2. Reverse transcription 
 
For mRNA analysis by qPCR technique, the RNA was converted to a 
complementary-DNA (cDNA). For this purpose the Superscript™ First-Strand 
Synthesis System (Invitrogen) was used. 500 ng of the RNA was mixed with 10 
ng random hexamers, 1 μl 10 mM dNTP mix (deoxyribonucleotides) and filled 
with DEPC-treated water to a total volume of 10 μl. Samples were incubated 
at 65 °C for 5 min for denaturation of the RNA and left on ice for 1 min. In the 
meanwhile 2 μl of 10x RT buffer, 2 μl DTT (0.1 M), 4 μl of MgCl2 (25 mM) and 
1 μl RNaseOUT inhibitor (40 U/μl) were  mixed. 9 μl of this reaction mixture 
was added to each sample and left on room temperature for 2 min. Then 1 μl 
Superscript™ II RT enzyme (50 U/μl) was added and left at 25 °C for further 
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10 min. Then the samples were incubated at 42 °C for 60 - 90 min before the 
enzyme was inactivated by heating the samples to 70 °C for 15 min. Before 
proceeding to amplification of the target cDNA the remaining RNA was 
digested by 1 μl RNase H. The cDNA was stored at -80 °C. 
 
 
3.2.5.3. Quantitative real-time PCR 
 
For the quantification of specific mRNA expression level a quantitative real-
time polymerase chain reaction (qPCR) was performed. 
For this purpose, QuantiTect® Primer assays (Qiagen, Germany) for the 
different target genes and primers specific for 18S rRNA levels were used from 
(Invitrogen, USA). Differences in RNA levels were detected by using a 
LightCycler™ LC480 (Roche Diagnostics) system which detects fluorescence of 
the dye SYBR® Green. It is a dye that binds to double stranded DNA by 
intercalating with the minor groove of the DNA double helix. During PCR the 
DNA amount and the signal of intercalating SYBR® Green increases 
exponentially, which can be monitored in real-time. The assay was performed 
particularly employing Lightcycler™ 480 SYBR® Green I Master Mix (Roche 
Diagnostics, Switzerland). The cDNA of each sample was diluted in RNase-free 
water 1:10. The reaction mix contained 7.5 μl SYBR® Green I Master Mix, 1.5 
μl primer solution and 4 μl PCR-grade water. 13 μl of the mixture was pipetted 
into each well of a PCR plate and 2 μl of the 1:10 diluted cDNA was added, 
followed by a brief spin in the centrifuge. The real-time qPCR was performed 
according to the manufacturer‘s instructions. Each sample was measured in 
triplicate. Data were analyzed using LightCycler™ LC480 software and 
further evaluated in Microsoft Excel. 
 
3.2.6. Transfection of VSMC  
 
In order to transfect VSMC several methods were tested. 
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3.2.6.1. Fugene HD 
 
The transfection of VSMC was performed in 12-well plates, using 1 X 105 
cells/well. Cells at 80% confluency were either covered by 750 µl DMEM 
containing 10% CS or were mitogen starved for 24 h. First a separate vial was 
prepared with 25 µl serum-free DMEM (HEPES 10 mM) and mixed with 1 µg 
of DNA. Then 1.5 µl/vial of Fugene HD was added followed by 15 min 
incubation. Before pipetting this mixture to the cells, 225 µl of 10% CS-
containing DMEM was added. Afterwards, the 12-well plate was centrifuged 
for 5 min at 800 g. Then, ZnCl2 was added to a final concentration of 250 µM 
and incubated for 4 h on 37 °C. Finally, cells were washed with PBS and grown 
in fresh 10% CS containing DMEM over night.  
 
 
3.2.6.2. Amaxa® 
 
Amaxa® Nucleofector® Technology was suggested to be the ideal tool to 
transfect primary mammalian smooth muscle cells. For this purpose we used 
the Basic smooth muscle cell Nucleofector® kit [Lonza Group Ltd. (Basel, 
Switzerland)] and a Nucleofector® devise. This technology is based on cell-
type-specific solutions and optimized electrical parameters for electroporation.  
The transfection of VSMC was done as follows: 
VSMC were grown at 37°C and 5% CO2 in DMEM containing 2 mM glutamine, 
100 U/ml penicillin/100 μg/ml streptomycin, and 10% calf serum to 80% 
confluency in a 75 cm2 flask. Cells between passages 8 to 12 were used. Growth 
medium was removed and cells were washed once with PBS, before incubation 
with 3 ml/75 cm2 trypsin/EDTA for around 2 min. Trypsin-reaction was 
stopped with Trypsin neutralization solution (Invitrogen), followed by cell 
counting in a cell viability analyser (ViCell™, Beckman Coulter, USA). 
1 x 106 cells were resuspended in 100 µl Nucleofector® Solution per sample at 
room temperature. Then the cell suspension was combined with 5 µg DNA 
(GFP plasmid and NFκB luciferase plasmid), transferred into the supplied 
cuvette, electroporated with program A33 and added into 500 µl pre-warmed 
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growth medium. This mixture was then transferred into 6-well plates and 
incubated at 37 °C and 5% CO2 for 18 hours. Then, transfected cells were 
treated with compound and/or stimulus before further analysis.  
 
 
3.2.6.3 Analysis of VSMC transfection 
 
For the analysis of the transfection efficiency we employed a Luciferase Kit 
(Promega). Every 6-well was lysed with 200 µl of the supplied lysis buffer. 50 
µl of the cell lysate was transferred into a black bottom 96-well plate before 
measurement in a 96-well plate reader (Tecan GENios Pro; Tecan Group Ltd., 
Männedorf, Switzerland). Samples were measured by monitoring the increase 
in fluorescence at a wavelength of 520 nm using an excitation wavelength of 
485 nm for the green fluorescence protein (GFP) levels. Luminescence of the 
luciferase was detected with an integration time of 2000 ms. 
 
 
3.2.7. Transfection of HEK-293 cells 
 
HEK-293 cells were transfected with the calcium phosphate transfection 
method in a 6-well plate, with a NFκB reporter gene plasmid, p50, p65, eGFP 
or empty vector. 100.000 HEK-293 cells were seeded in 10% FBS containing 
DMEM, 2 mM glutamine and 100 U/ml penicillin/100 μg/ml streptomycin.  
For tranfections 85 µl of H2O, 1 µg of DNA and 12.5 µl of 2 x 2 M CaCl2 were 
mixed and added drop wise to 100 µl of a 2  HBS solution. After incubation for 
at least 10 min at RT, the mixture was vortexed added drop wise to the cell 
culture dish and incubated over night. The analysis of HEK-293 transfection 
was performed as described in 3.2.3.6 for VSMC. 
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3.2.8. Wound healing assay (adapted from Christa Czaloun) 
 
For the wound healing or scratch assay cells were grown to a confluent 
monolayer, scratched, and the area of the scratch was determined before and 
after PDGF-BB stimulation. To exclude that proliferation contributes to 
scratch closure the assay was stopped after 20 h because the VSMC used 
divided 26 - 28 h after stimulation. VSMC were seeded in 6-well plates (0.8 x 
106 cells/ well). To ensure that at 0 h and 20 h the very same area of each 
scratch is captured perpendicular lines were drawn at the bottom side of the 
plates. When confluence was reached after 24 h, cells were serum-starved for 
another 24 h, scratched with a 1000-μl pipette tip and after washing with PBS 
further serum-starved for 24 h. Cells were pretreated with test compounds or 
vehicle (DMSO 1%) for 30 min and subsequently stimulated with PDGF-BB 
(10 ng/ml) for 20 h. The scratch area was captured with a light microscope just 
before PDGF-treatment and 20 h later. The cell re-colonization rate was 
evaluated by measuring the cell free area of each scratch, using Cell Profiler 
software (Broad Institute, Cambridge, MA, USA). 
 
 
3.2.9. Saphenous vein model (adapted from Iris Zeller) 
 
This assay was performed by Iris Zeller in the laboratory of Prof. David 
Bernhard, Allgemeines Krankenhaus (AKH) in Vienna.  
For organ culture experiments, remnants of saphenous veins from patients 
undergoing CABG were collected, opened longitudinally, attached to silicone 
patches and incubated with culture medium (RPMI 1640, 30% serum, heparin 
8 mU/mL, antibiotics) for 2 weeks to induce intimal hyperplasia. The potential 
inhibition of intimal hyperplasia by tylophorine was tested by the addition of 
different concentrations of tylophorine, or DMSO to the organ cultures. The 
medium containing tylophorine or DMSO was replaced by fresh medium every 
second day. Baseline samples were fixed directly after preparation of fresh 
tissue and represent the status of the vessel prior to organ culture (adopted 
from Reisinger U et al., 2009). 
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3.2.10. Statistical analysis  
 
Data are expressed as means ± SD, if not stated otherwise. Statistical 
significance was determined by ANOVA using Tukey post hoc test. 
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4. Results 
  
4.1. Characterization of Vascular Smooth Muscle Cells 
 
VSMC from rat thoracic aortas of Sprague Dawley rats were provided as 
described in the materials and methods section. Further, rat VSMC from 
thoracic aorta of Fischer rats were isolated by myself. To confirm their identity 
cells were stained with a fluorescent-labeled α-smooth muscle actin antibody 
(Fig. 4), a specific marker for vascular smooth muscle cells (Gabbiani G et al, 
1981). No contamination with other cell types could be detected.  
 
     
4.2. Impact of tylophorine on VSMC proliferation 
 
4.2.1. Inhibition of VSMC proliferation (crystal violet staining) 
 
To investigate a potential anti-proliferative activity of tylophorine against 
VSMC we first used crystal violet to stain the biomass obtained after calf 
serum (CS) stimulation. VSMC were serum-starved, treated with the indicated 
concentrations of tylophorine and stimulated with 10% serum for 48 h prior to 
the addition of crystal violet. Figure 5 shows that tylophorine inhibits 
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proliferation of VSMC in a concentration dependent manner with highest 
inhibitory activity at 1000 nM.  
 
     
This assay is fast, easy and cost effective and delivers first useful but rough 
hints about the anti-proliferative properties of a compound. In order to confirm 
growth inhibition by tylophorine with a more precise method, we next assessed 
the amount of DNA replication in the presence of tylophorine.  
 
 
4.2.2. Inhibition of VSMC proliferation (DNA-synthesis)  
 
To determine the ability of tylophorine to interfere with DNA 
replication/synthesis in the cell, we performed a BrdU-incorporation assay. 
Here, we used PDGF-BB instead of calf serum as stimulus to trigger the 
proliferation of VSMC. PDGF-BB is the most potent pro-proliferative mitogen 
for VSMC and its usage limits the range of activated signaling pathways in the 
cell compared to serum which contains multiple growth factors.   
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We added tylophorine in concentrations ranging from 1 nM to 1000 nM to 
PDGF-BB-activated (20 ng/ml) VSMC. The assessment of DNA synthesis 
shows that tylophorine potently inhibits PDGF-BB-induced proliferation in a 
dose-dependent manner with an IC50 of 128.15 nM (+/- 44 nM) and a complete 
block at 1 µM (Fig. 6).  
 
 
4.2.3. Accumulation of VSMC in G1-phase 
 
Due to the strong inhibition of DNA-synthesis by tylophorine in VSMC, we 
further analyzed its effect on the progression of cells through the cell cycle 
phases. Quiescent VSMC were treated with tylophorine and PDGF-BB for 20 h 
and then stained with propidium iodide (PI) to allow flow cytometric 
measurement of the DNA-content of single cells (Fig. 7). PDGF-BB stimulation 
of VSMC leads to progression through the cell cycle as seen by higher 
percentages of cells in S-/G2-phase compared to serum-starved cells being in 
G1-G0 of the cell cycle. Tylophorine-treated (300 nM and 1 µM) VSMC showed 
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an accumulation of cells in G1-phase of the cell cycle similar to the starved 
unstimulated cells. A clear subG1-peak indicative for cell death was not 
observed. 
 
     
 
Drawback of this method is that it is difficult to clearly distinguish between 
apoptotic and necrotic cells or cell debris due to distortion of the cells during 
the experimental procedure. Furthermore, it is not possible to distinguish 
between a true G1-phase or a very early S-phase arrest. Therefore, we went 
on, first, to prove that tylophorine is not inducing apoptosis and, second, to 
analyze its ability to stop VSMC in S-phase of the cell cycle.   
 
 
4.2.4. Tylophorine does not induce apoptosis 
 
To test whether tylophorine is inducing apoptosis in VSMC we used an 
Annexin V-FITC Apoptosis Detection Kit as described in the material and 
methods part. In apoptotic cells, phosphatidylserine PS is translocated from 
the inner to the outer leaflet of the plasma membrane, exposing PS to the 
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external environment, whereas PS is in normal cells located on the cytoplasmic 
side of the cell membrane. Annexin V has a high affinity for PS.  
Figure 8 depicts the amount of annexin V positive VSMC in a DMSO-, 
tylophorine- or H2O2-treated population. The DMSO control contained 5 % of 
annexin V positive cells, whereas the H2O2 treated cell population, used as 
positive apoptotic control, showed around 25 % positive VSMC. The amount of 
annexin V positive cells in the tylophorine-treated cell population is on the 
level of the negative control. Therefore, treatment of VSMC with 1 µM 
tylophorine does not induce apoptosis.  
     
 
4.2.5. Tylophorine is not an S-phase, but a true G0/G1-arrestor 
 
To further examine if tylophorine is a true G1- and not an early S-phase-
arrestor, VSMC were treated with 1 µM aphidicolin, a reversible inhibitor of 
DNA-polymerase α and δ, which stops the cell cycle in early S-phase (Fig. 9). 
After removal of aphidicolin, cells were treated with 1% DMSO or aphidicolin 
or 1 µM tylophorine and examined for BrdU incorporation. Continuing 
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treatment with aphidicolin completely inhibits BrdU incorporation (the 
percentage of BrdU-incorporating cells is around 1%), whereas treatment with 
1 µM tylophorine and DMSO allows BrdU incorporation and thus progression 
through S-phase. Compared to DMSO, tylophorine treated cells pass slower 
through S-phase as seen by a lag in BrdU incorporation (up to 30% after 6 h).  
 
     
 
Overall, these findings indicate that tylophorine dose dependently inhibits 
VSMC proliferation by arresting starved cells in the G0/G1-phase of the cell 
cycle, without inducing apoptosis in concentrations up to 1 µM. 
 
To consolidate that tylophorine is a true G1-phase arrestor in rat aortic VSMC 
we investigated the phosphorylation status of the retinoblastoma protein, 
which is an important regulator of the G1/S-phase transition of the cell cycle. 
S-phase entry is highly regulated and the hyper-phosphorylation of the 
retinoblastoma protein is a prerequisite (Sherr CJ and Roberts JM, 1999). 
Treatment of rat aortic VSMC with PDGF-BB (20 ng/ml) led to a time- 
dependent increase in phosphorylation of the retinoblastoma protein on 
residue S807/811 which is blocked by 1 µM tylophorine (Fig. 10). These data 
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underline that tylophorine is a G1-phase-arrestor in PDGF-BB-activated rat 
aortic VSMC. 
 
 
 
4.3. Influence of tylophorine on signaling cascades 
 
4.3.1. Early PDGF-BB-induced signaling events 
 
In order to get insight into the underlying mode of action, we next examined 
important early key signaling molecules leading to proliferation in VSMC upon 
PDGF-BB stimulation. These include the kinase Akt, the mitogen-activated 
protein (MAP)-kinases Erk 1/2 (p42/p44), p38MAPK and c-Jun N-terminal 
kinase (JNK), and the Signal transducer and activator of transcription 3 
(STAT3) (Fig. 11).  
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As seen in figure 11, PDGF-BB (20 ng/ml) treatment for 10 min leads to 
phosphorylation of the kinase Akt, p42/44, p38, JNK and transcription factor 
STAT3. Preincubation of cells with 1 μM tylophorine for 30 min followed by 
stimulation with PDGF-BB did not influence the phosphorylation of these 
early signaling kinases. Therefore tylophorine is not causing a G1-phase arrest 
via inhibition of these kinases or transcription factors. 
 
 
4.3.2. Role of NFκB in PDGF-BB signaling 
 
In many cell types the transcription factor Nuclear factor κB (NFκB) regulates 
cell cycle progression and proliferation. However, the role of NFκB for the 
proliferation of VSMC is controversial (Selzman CH et al., 1999; Erl W et al., 
1999; Mehrhof FB et al., 2005). Therefore, we needed to verify the influence of 
PDGF-BB on the activation of NFκB and a possible modulation by tylophorine. 
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4.3.2.1. NFκB-luciferase reporter gene assay 
 
To investigate a putative influence of tylophorine via the NFκB pathway on 
the proliferation of VSMC we aimed to perform NFκB-dependent luciferase 
reporter gene assays. For this reason, transfection of VSMC with plasmids 
containing an NFκB-dependent reporter gene, were obligatory. Due to general 
problems with viability of VSMC after transfection we had to try several 
different transfection agents and methods.  
According to literature, primary SMC should be transfectable with 
plasmids/vectors using Fugene 6 reagent (Elmadbouh I et al., 2004). The 
transfection was performed as described in materials and methods section. 
First tests with Fugene 6 showed a low transfection efficiency using a GFP 
plasmid (< 10% GFP-positive cells). The usage of Fugene HD reagent increased 
the number of GFP-positive cells. Still, in our primary cells the transfection 
efficiency with GFP, analyzed by fluorescence microscopy, was too low to 
perform conclusive experiments. Therefore, we tried a different method using 
the Amaxa system, as described in materials and methods, which combines 
liposomal and electroporetic Transfection procedures. However, here the 
biggest occurring problem was cell death (< 5% viable cells 24 h after 
transfection).  
To check the vectors for the reporter gene luciferase assay and verify that they 
are not the source of our problems, the transfection was performed in human 
embryonic kidney (HEK) cells, followed by analysis of fluorescence and 
luminescence of each sample.  
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Figure 12 demonstrates that co-transfection of the expression vectors for 
NFκB and its subunit p65 highly increases luciferase activity of the NFκB-luc 
plasmid. The GFP expression was used for normalization. The empty vector 
pcDNA3 alone, which was used for negative control, has no influence on 
luciferase activity. Co-transfection of NFκB and the p50 subunit leads to a 
minor increase of luminescence. TNFα (2 ng/ml) treatment of single NFκB-luc 
transfected cells slightly increases luciferase activity. Therefore, we proved 
that the plasmids seem to work in a different cell type than VSMC.  
Overall, despite major efforts and confirmed functional expression vectors, we 
were not able to succeed in sufficiently high transfection efficiency in VSMC to 
perform luciferase reporter gene assays in order to anwer the question 
whether VSMC respond to PDG by activation of the NFκB pathway. Therefore 
we focused on IκBα levels. 
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4.3.2.2. Tylophorine has no influence on IκBα levels 
 
To exclude an inhibition of proliferation by tylophorine via inhibition of the 
transcription factor NFκB we investigated the inhibitor of κB alpha (IκBα) 
levels. IκBα needs to be degraded for NFκB activation (Ferreiro DU and 
Komives EA, 2010).  
 
     
 
We show (Fig. 13) that treatment of VSMC with TNFα (10 ng/ml) is leading to 
degradation of IκBα after 15 min. PDGF-BB is not inducing NFκB activation, 
demonstrated as an inability of PDGF-BB (20 ng/ml) to degrade IκBα. 
Furthermore tylophorine has no influence on IκBα levels. Hence, PDGF-BB is 
not activating NFκB by degradation of IκBα in rat aortic VSMC. Furthermore, 
tylophorine is not influencing NFκB-activation and therefore not inhibiting the 
PDGF-BB-induced proliferation of VSMC via this pathway.  
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4.4. Cyclin D1 is down regulated by tylophorine 
 
Next, we examined the cell cycle-regulatory protein cyclin D1 and its 
susceptibility to tylophorine. Cyclin D1 is considered to be G1-phase specific, 
the binding partner of CDK4/6 and essential for the phosphorylation of 
retinoblastoma protein (Sherr CJ and Roberts JM, 1999). Cyclin D1 up 
regulation is necessary for the cell to pass from G1- to S-phase of the cell cycle 
(Sherr CJ, 1995) and lack of cyclin D1 leads to a G1-phase arrest.  
To see an influence of tylophorine on cyclin D1 protein levels we pretreated 
quiescent VSMC with 1 µM tylophorine or vehicle and stimulated them with 
PDGF-BB (20 ng/ml) for the indicated time. PDGF-BB stimulation led to a 
time-dependent increase of cyclin D1 levels in control cells. Tylophorine-
treated VSMC showed highly reduced cyclin D1 protein levels which are even 
lower than basal levels in control VSMC (Fig. 14).  
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4.5. Influence of mitogens on cyclin D1 expression levels 
 
To check whether the down regulation of cyclin D1 by tylophorine occurs 
independent of the stimulus or cell cycle phase we investigated the cyclin D1 
protein levels of mitogen-starved quiescent (Fig. 15) and calf-serum stimulated 
rat aortic VSMC (Fig. 16).  
 
     
Figure 15 shows that tylophorine leads to down regulation of basal cyclin D1 
expression levels in quiescent VSMC already within 15 min. In 
unsynchronized serum-stimulated VSMC, tylophorine leads to rapid down 
regulation of cyclin D1 expression levels as well (Fig. 16).  
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Compared to starved VSMC, serum-stimulated VSMC exhibit higher cyclin D1 
levels in control and tylophorine-treated cells. Nevertheless, tylophorine has 
an inhibitory effect on proliferation in serum-stimulated VSMC as evident in a 
resazurin conversion assay (Fig. 17) (IC50 = 468 nM ± 144 nM). At 1 μM 
tylophorine proliferation of VSMC in serum is completely inhibited, as 
expected from the observed reduction of cyclin D1 in these cells. 
 
     
 
4.6. Influence of tylophorine on cyclin A  
 
To demonstrate the specificity of cyclin D1 degradation, we further analyzed 
the cell cycle-regulatory protein cyclin A and its susceptibility to tylophorine 
by western blotting. Cyclin A is necessary for S-/G2-phase progression and the 
binding partner of CDK2 (Voitenleitner C et al., 1997). Here, VSMC were 
pretreated with 1 µM tylophorine or vehicle and stimulated with 10% calf-
serum for the indicated time.  
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As seen in figure 18 the protein levels of cyclin A are not changed by 
tylophorine treatment. Further, starved VSMC which were treated with 1 µM 
tylophorine or vehicle without stimulation do not express cyclin A (Fig. 19). 
 
     
 
4.7 No influence of tylophorine on CDK4, but p21 expression levels 
 
Furthermore, we examined the inhibitor of the CDK4-cyclin D1-complex p21. 
The p21 (CIP/KIP) protein is a cyclin dependent kinase inhibitor which 
inhibits CDK4-cyclin D1 complexes (Afshari CA et al., 1996). We analyzed the 
influence of 1 µM tylophorine on p21 expression levels by western blotting. 
VSMC were pretreated with tylophorine or vehicle and stimulated with serum 
for the indicated time. As demonstrated in figure 20, p21 protein expression 
levels are down regulated by tylophorine treatment.   
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As two components of the CDK4-cyclin D1-p21 complex are degraded in 
tylophorine treated cells we analyzed the CDK4 expression levels. As shown in 
(Fig. 21), CDK4 expression levels are not changed.  
 
     
Not just cyclin D1, but also its inhibitory binding partner p21 are down 
regulated by tylophorine treatment of VSMC. But the expression levels of the 
kinase CDK4 seem to be unaffected. 
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4.8. No effect of tylophorine on total p53 expression levels 
 
Due to the fact that p21 is the transcriptional target of the tumor suppressor 
protein p53 (Jung YS et al., 2010), we determined the total p53 levels after 
tylophorine treatment. VSMC were stimulated with PDGF-BB (20 ng/ml) as 
indicated in the presence/absence of 1 µM tylophorine. As seen in figure 22 
there is no difference in p53 expression levels between control and tylophorine- 
treated cells, indicating that the induced p21 levels in tylophorine-treated 
VSMC are not due to altered p53 levels. The activity of p53 is also regulated by 
posttranslational modifications, such as phosphorylation and acetylation 
(Brooks CL and Gu W; 2003). The impact of tylophorine on p53 
phosphorylation sites is minimal and will get extensive attention in chapter 
4.11.. 
 
     
4.9. Mechanism of cyclin D1 and p21 degradation 
 
The tylophorine-induced down regulation of cyclin D1 and p21 protein levels in 
rat aortic VSMC raises the question whether cyclin D1 levels are reduced by 
inhibition of protein synthesis on the transcriptional or translational level or 
by increased degradation via the proteasomal pathway.  
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4.9.1. No effect of tylophorine on cyclin D1 and p21 mRNA levels 
 
To answer this question, we first performed qRT-PCR-analysis (Fig 23). We 
pretreated quiescent VSMC with 1 µM tylophorine and stimulated them for 
0.5 h and 2 h with PDGF-BB (20 ng/ml). Then RNA was extracted, transcribed 
to cDNA and subjected to qRT-PCR analysis as described in materials and 
methods. The analysis revealed that tylophorine (1 µM) has no significant 
influence on cyclin D1 mRNA levels.  
 
     
Further qPCR analyses of p21 mRNA levels are depicted in figure 24. 
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The p21 mRNA levels seem to be slightly down regulated after 30 min of 
tylophorine treatment and up regulated after 2 h. But these differences are not 
significant.  
 
 
4.9.2. Proteasome-dependent cyclin D1 degradation  
 
In order to investigate the role of the proteasome for cyclin D1 reduction by 
tylophorine, we employed the known proteasome inhibitor MG132 (Fig. 25). 
VSMC were pretreated with MG132 (50 µM) for 1 h and then treated with 
1 µM tylophorine or vehicle for 2 h as indicated. 
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The immunoblot demonstrates that down regulation of cyclin D1 levels by 
tylophorine treatment in VSMC is blocked by MG132.  
This finding proves that tylophorine leads to down regulation of cyclin D1 via 
the proteasomal pathway in rat aortic vascular smooth muscle cells, which 
most likely account for the growth inhibition of tylophorine-treated VSMC. 
 
 
4.10. Tylophorine has a comparable effect on HUVSMC 
 
In order to exclude species specific effects of tylophorine we aimed to reproduce 
the anti-proliferative effect of tylophorine on human smooth muscle cells. 
Consequently we tested tylophorine‘s activity on primary human umbilical 
vein smooth muscle cells (HUVSMC).  
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First we show by a resazurin conversion assay (Fig. 26) that tylophorine is 
able to inhibit the proliferation of HUVSMC dose-dependently (IC50 = 164 nM 
± 49 nM). At 1 μM tylophorine proliferation is completely blocked.  
 
     
Second we demonstrate by Immunoblot analysis that tylophorine leads to 
rapid degradation of cyclin D1 (Fig. 27), with first effects seen already after 15 
min of treatment. This degradation of cyclin D1 protein levels can also be 
blocked in HUVSMC by proteasomal inhibition with 50 µM MG132 (Fig. 28).  
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Therefore we conclude that tylophorine leads to inhibition of proliferation and 
proteasomal degradation of cyclin D1 in human smooth muscle cells as it does 
in rat aortic VSMC. 
 
 
4.11. Pepchip kinase array - p53 phosphorylation on serine 9 
 
To find the target of tylophorine in the cell we also started an unbiased kinase 
array approach in parallel. This Pepchip™ kinase array was performed by the 
cooperation partners in the Netherlands – Pepscan. For this experiment whole 
cell extracts of tylophorine-treated and vehicle-treated VSMC were used with 
respect to their ability to lead to phosphorylation of selected peptide sequences, 
which are specific for a certain protein. (See materials and methods section). 
The output data of this assay resulted in a list of proteins in which the 
phosphorylation of a specific amino acid residue was activated or inhibited by 
our compound as well as the list of suggested kinases responsible for these 
phosphorylations. The table in section 7.2. shows proteins where the 
phosphorylation status was modulated by tylophorine. The data analysis 
revealed a 43 fold induction of p53 phosphorylation on serine 9 presumably via 
ATM/ATR kinase. This result needed to be confirmed by further immunoblot 
analyses.  
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4.11.1. Confirmation of kinase array results  
The outcome of the kinase array led to the hypothesis that tylophorine 
treatment of VSMC induces the phosphorylation of p53 on serine 9 about 43-
fold. Unfortunately, the antibodies available for examining phosphorylation of 
p53 were raised against the human protein. Therefore, we used HUVSMC and 
specific antibodies against human p53 serine 9 in order to test the impact of 
tylophorine on phosphorylation of p53 on serine 9 and other phosphorylation 
sites. Immunoblots for p53 serine 9 phosphorylation sites were performed by 
our master student Päivi Gruzdaitis. 
 
4.11.1.1. Effect of tylophorine on p53 serine 9  
For this, HUVSMC were treated with 1 µM tylophorine or vehicle for the 
depicted time, lysed and subjected to western blot analysis for the p53 
phosphorylation at serine 9 and total p53 levels. 
 
  
 
Figure 29 demonstrates that (I) serine 9 phosphorylation of p53 is hardly 
detectable and (II), at least, not upregulated 43-fold by tylophorine as expected 
from the kinase array results. Tylophorine seems not to have an influence on 
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total p53 levels either. Thus, the result of the pepscan kinase array could not 
be confirmed in our cell system.  
 
 
4.11.1.2. Effect of tylophorine on other p53 phosphorylation sites 
 
To exclude differences in the phosphorylation status of p53 on several other 
phosphorylation sites, we performed western blot analysis for the serine sites 
15 and 46. HUVSMC were treated with tylophorine or vehicle for the indicated 
time and subjected to western blot analysis. In figure 30 there seems to be no 
change in the phosphorylation status of p53 on serine 46 upon tylophorine 
treatment. However, treatment of HUVSMC with 1 µM tylophorine induces a 
reproducible dephosphorylation of p53 on serine 15.  
 
  
 
4.12. Tylophorine inhibits HUVSMC proliferation 
 
Due to the strong inhibition of HUVSMC proliferation by tylophorine 
treatment, we further analyzed its effect on the progression of unsynchronized 
HUVSMC through the cell cycle phases. HUVSMC were treated with 
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tylophorine for 24 h to 120 h and stained with propidium iodide (PI) to 
measure the DNA-content of single cells (Fig. 31).  
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Figure 31 A. depicts raw flow cytometry results of HUVSMC treated for 24 h 
or 120 h with 1 µM tylophorine or vehicle, whereas figure 31 B. shows the the 
evaluation of all three independent experiment. 
The differences in the cell cycle distribution of tylophorine- or DMSO-treated 
HUVSMC for 24 h are minor. Tylophorine-treated cells exhibit a broader and 
higher percentage of cells in G1-phase compared to DMSO-treated cells. After 
120 h, tylophorine-treated HUVSMC show a high number of cells in S-phase, 
and not in G1-phase as seen in and expected from starved rat VSMC. DMSO-
treated cells demonstrate a contact inhibition after 120 h and are therefore 
arrested in G1-phase. Therefore, they are arrested in G1-phase. The cell 
populations in G1- and G2-phase of the cell cycle in tylophorine-treated cells 
are similar to the cell populations seen in untreated cells at the 0 h time point. 
This might indicate that tylophorine-treated cells are slowed down in the 
progression through S-phase or even ―frozen‖ in this state. But it was 
obviously visible from microscopic pictures that the cells do not divide at all 
(Fig. 32). Documented by light-microscopy, there was no increase in density of 
tylophorine-treated cells over 120 h.  
A subG1-peak indicative for cell death was not observed either (Fig. 31 A). 
Further, we made the observation that side and forward scatter, indicative for 
size and granularity, were increased by tylophorine treatment. Since, PI stains 
the whole DNA-content, including mitochondrial DNA of single cells, we 
hypothesized that tylophorine increases the number of mitochondria per cell. 
Thus the mitochondrial DNA-content could account for the presumable S-
phase peak in the depicted histogram blots.  
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4.13. Tylophorine increases the mitochondrial mass 
 
To analyze changes of the mitochondrial mass in HUVSMC, cells were treated 
with tylophorine or vehicle for 24 to 120 h and stained with Mitotracker™ 
green. Figure 33 shows that tylophorine treatment of HUVSMC increased the 
total mitochondrial mass in the cell over time. Depicted is the ratio of 
tylophorine- vs DMSO-treated cells. Statistical analysis (ANOVA/Tukey) did 
not reveal a significant difference between DMSO- and tylophorine treated 
cells. However, figure 34 is showing, at least, a tendency of a 2-fold higher 
mitochondrial mass after 120 h of tylophorine treatment. 
 
  
4.14. Effect on “cycling” VSMC 
 
Due to the results of the FACS analysis for HUVSMC, where we observed a 
slowdown in the progression through S-phase of tylophorine-treated cells, we 
further tested, if tylophorine can inhibit the cell cycle in G1-phase in 
unsynchronized serum-stimulated rat VSMC. Therefore, VSMC were treated 
with tylophorine for 72 h to 120 h and stained with propidium iodide (PI) to 
measure the DNA-content.  
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Figure 34 demonstrates that tylophorine-treated VSMC showed a comparable 
distribution of cells in G1-, S- and G2-phase over time as already discovered in 
HUVSMC. A specific G1-phase arrest is not induced by tylophorine unlike in 
mitogen-starved and PDGF-BB stimulated VSMC as seen in section 4.2.3. In 
contrast, cycling VSMC are obviously retarded or stalled in S-phase by 
tylophorine.  
 
 
4.15. Migration of VSMC – Wound healing assay 
 
Proliferation and migration contribute to neointima formation. PDGF-BB is 
not only the most potent proliferative but also the most effective migratory 
stimulus for VSMC. Here, we examined the influence of tylophorine on VSMC 
migration via scratch assay (See materials and methods).  
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Figure 35 demonstrates that tylophorine treatment reduces the PDGF-BB-
stimulated migration by 80%. Whether this inhibition is linked to cyclin D1 
degradation or other targets needs to be investigated. 
 
 
4.16. Inhibition of neointimal thickening 
 
In cooperation with the research group of PD Dr. David Bernhard at the AKH 
Vienna, tylophorine was tested on its ability to inhibit intimal thickening in a 
human saphenous vein model in vitro. The assay was performed as described 
in the materials and methods section. Tylophorine was used in three different 
concentrations - 300 nM, 1 µM and 3 µM. 
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As seen in figure 36, tylophorine is able to inhibit intimal thickening 
significantly in every tested concentration. Therefore, tylophorine seems to be 
a promising compound in the anti-proliferative in CABG or PCI therapy.  
 
 
4.17. Plant extracts and natural compounds as anti-proliferative drugs 
 in VSMC  
 
4.17.1. Screening of plant extracts  
 
Natural products represent a rich source for the identification of new lead 
structures and novel molecular mechanisms. Drugs from nature have always 
played an important role in human health care. Therefore, we have chosen to 
lean on the traditional medicinal knowledge to find drugs with new anti-
proliferative effects on VSMC.  
Around 100 extracts of plants used in traditional Chinese medicine or in 
Austrian folk medicine with anti-inflammatory properties were tested for their 
anti-proliferative activity in VSMC (Diploma thesis, Thomas Nakel, 2011). For 
this, we employed a resazurin conversion assay. The extract with the highest 
inhibitory activity in this small screening program was from Peucedanum 
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ostruthium. Therefore, we chose this extract for further investigation and 
subjected it to fractionation, aiming for the identification of the active 
principle. 
 
 
4.17.2. Impact of Ostruthium Peucedanum on VSMC 
 
4.17.2.1. Inhibition of VSMC proliferation 
 
To examine the potential of Peucedanum ostruthium rhizome to inhibit the 
serum-stimulated proliferation of VSMC, we subjected the DCM-extract to 
calf-serum activated VSMC in concentrations ranging from 3 to 30 µg/ml 
(Fig. 37). After 30 min pretreatment with the extract, mitogen-starved VSMC 
were stimulated with 10% calf-serum. Serum-stimulated VSMC were taken as 
positive and mitogen-starved cells as negative controls. Our resazurin 
conversion assay analysis revealed that the DCM-extract of P. ostruthium 
inhibits the proliferation of serum-stimulated rat aortic VSMC with an IC50 of 
24 µg/ml ± 14 µg/ml significantly.  
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4.17.2.2. The extract contains 7 major coumarins  
 
With this promising finding we prove that the DCM-extract of P. ostruthium 
has inhibitory activity on rat aortic VSMC proliferation and therefore we 
further fractionated and separated the extract by HPLC to elucidate the active 
compounds (Silvia Vogl, Research group of Prof. Kopp, University of Vienna, 
Vienna). 
The HPLC investigations led to the identification of seven coumarins in the 
DCM extract of Peucedanum ostruthium rhizomes. As a first separation step 
we performed preparative HPLC (Fig. 38). 
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With further purification on silica gel eluted with hexane/ ethyl acetate we 
could isolate seven (furano-) coumarins, oxypeucedanin hydrate, 
oxypeucedanin, ostruthol, imperatorin, osthole, isoimperatorin and ostruthin 
(table 2).  
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# compound R1 R2 
1 
oxypeucedanin 
hydrate 
H 
 
2 oxypeucedanin H 
O
O
 
3 ostruthol H 
O
O
OH
O
 
4 imperatorin 
O
 
H 
6 isoimperatorin H 
O
 
 
OO O
R1
R2
linear furanocoumarins 
 
 
 
OH
O
OH
 
 
simple coumarins 
 
O OR2
R3
R1  
# compound R1 R2 R3 
5 osthole 
 
OMe H 
7 ostruthin H OH 
 
 
 
Table 2. Structural classification of the main coumarins in the DCM extract of Peucedanum 
ostruthium rhizomes. 
 
 
Quantification measurements of the coumarin content in the DCM extract of 
Peucedanum ostruthium rhizome resulted in ostruthin as the main coumarin 
(41% of the total coumarin content), followed by oxypeucedanin (18%), 
ostruthol (13%), imperatorin (12%),  isoimperatorin (9%), oxypeucedanin 
hydrate (6%) and osthole composing just 1%. The total coumarin content in 
this extract made up 78%, whereas the amount on gram dry weight of drug 
made up only 6%.  
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4.17.2.3. Effect of the major compounds  
 
After the isolation of the major compounds of the P. ostruthium extract, we 
tested each of them for its anti-proliferative activity on serum-stimulated 
VSMC. Imperatorin, isoimperatorin, ostruthin, ostruthol, osthole, 
oxypeucedanin and oxypeucedanin hydrate, were subjected to resazurin 
conversion assay analysis in a concentration of 30 µM (Fig. 39).  
 
  
 
The result demonstrates that ostruthin is the only compound of this extract 
which significantly inhibits serum-stimulated VSMC proliferation. Structural 
similar furanocoumarins to ostruthin, tested in this assay, have no effect on 
the proliferation of VSMC either.  
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4.17.2.4. Activity of structural related furano-/coumarins 
 
To validate the effect of ostruthin on VSMC proliferation we further tested 
several structural similar furano-/coumarins in the resazurin conversion assay 
(Fig. 40). 
 
  
 
None of these compounds have an inhibitory effect on the proliferation of 
VSMC. Statistical analysis did not reach significance. Their structure is 
depicted together with all tested coumarins in table 3 in section 7.2.2.. 
Therefore, Ostruthin is the compound responsible for the significant inhibitory 
effect of the Peucedanum Ostruthium extract. 
 
 
 
Results    
 
100 
 
4.17.2.5. Ostruthin inhibits DNA-synthesis 
To further examine the potential of ostruthin to inhibit VSMC proliferation we 
subjected it to a BrdU-incorporation assay in concentrations ranging from 
1 µM to 30 µM (Fig. 41).  
 
  
The assessment of DNA-synthesis shows that ostruthin potently inhibits 
serum-induced proliferation in a dose-dependent manner with an IC50 of 17 
µM ± 6 µM.  
In this study, two new important findings have been made. We discovered that 
the DCM-extract of Peucedanum ostruthium inhibits the proliferation of 
VSMC. Furthermore, we were able to track down the activity of this extract to 
a single compound, which is responsible for the inhibitory activity on serum-
stimulated VSMC proliferation - ostruthin. 
   
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION 
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5. Discussion 
 
5.1. Anti-proliferative activity of tylophorine and its molecular mode 
   of action 
 
In the last years several research groups demonstrated that tylophorine is able 
to inhibit proliferation in various cancer cell systems (Staerk D et al., 2003; 
Gao W et al., 2004 and 2007; Wei L et al., 2007; Wu CM et al., 2009). In this 
study we showed that tylophorine is a cell cycle arrestor in VSMC and 
HUVSMC as well as an inhibitor of neointima thickening in human umbilical 
vein organ cultures. Here we reveal that tylophorine has a unique mechanism 
of action, characterized by down regulation of cyclin D1 via a proteasome-
dependent pathway leading to cell cycle arrest. We could prove that this 
mechanism is species- and mitogens-independent by employing rat and human 
smooth muscle cells, as well as starved, PDGF-BB- and serum-stimulated 
cells.  
First we demonstrated that (-)-R-tylophorine inhibits the proliferation of 
PDGF-BB and calf-serum stimulated rat aortic VSMC in a dose-dependent 
manner with an IC50 of 128.15 ± 44 nM for PDGF-BB-, or 468 nM ± 144 nM for 
serum-treated cells.  These differences in the IC50 might be due to differences 
between the employed assay with regard to sensitivity and readout. The IC50 
for PDGF-BB treated cells were gained by employing a luminometric BrdU-
incorporation assay, which measures DNA synthesis, whereas the IC50 value 
for calf-serum stimulated VSMC was assessed by a fluorescence-based 
resazurin conversion assay, which gives a measure for the metabolic activity of 
the cells. Further, calf-serum contains several growth factors, and therefore 
elicits a stronger mitogenic response which may be harder to inhibit by 
tylophorine than that triggered by PDGF-BB alone.  
Studies employing the (-)-R-tylophorine are generally scarce. Previous 
publications demonstrating the anti-proliferative effect of tylophorine on 
cancer cells (Gao W et al., 2004; Shiah HS et al., 2006) are using the (+)-S-
tylophorine or analogues. Just Staerk and colleagues show an effect of (-)-R- 
tylophorine on human KB-3-1 cells and KB-V1 cancer cells with an IC50 of 
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around 200 nM. Hence, tylophorine inhibits the proliferation of VSMC in a 
similar concentration range. This result, together with the fact that 
tylophorine inhibits human and rat cells, suggests that tylophorine influences 
elementary mechanisms in the cell.  
These mechanisms obviously do not induce apoptosis in the cell. VSMC 
apoptosis eventually contributes to plaque rupture in an atherosclerotic lesion. 
An optimal lead structure for anti-restenotic drugs is inhibiting the 
proliferation of VSMC, but not inducing cell death. With our annexin V 
staining assay, we could point out, that tylophorine is not inducing apoptosis. 
The result in figure 8 demonstrates that tylophorine treatment does not 
increase membrane bound annexin V levels in these cell populations. Though, 
annexin V is a good marker for the detection of apoptosis, the assay would 
have performed better, having simultaneous PI staining results and allowing 
for discrimination between apoptotic and necrotic cells. PI is not passing the 
healthy plasma membrane. Therefore PI positive cells are an indicator for 
dead cells. But due to problems with this double staining and an appropriate 
positive control we had to rely on the annexin V staining results. Experiments 
using doxorubicin as an apoptosis-inducing agent for VSMC failed due to high 
toxicity and interferences with the fluorescence detection. Doxorubicin 
treatment of VSMC did not just lead to cell destruction, but to a color-shift in 
the measured fluorescence spectrum, which could not be satisfyingly 
compensated. Thus our focus lay on H2O2 which was already published to be 
probably involved in VSMC apoptosis (Li PF et al., 1997).  Indeed, H2O2 led to 
an increase in annexin V positive VSMC and could therefore be employed for 
the FACS measurement as positive control. Nevertheless, the annexin V 
positive cell population of tylophorine treated VSMC does not exceed negative 
control levels. Therefore, an influence of apoptosis or necrosis as an anti-
proliferative effect can be excluded.   
Further cell cycle analyses of PDGF-BB-stimulated VSMC indicate an 
accumulation of cells in G1-phase of the cell cycle in the presence of 
tylophorine. This FACS analyses alone cannot substantiate a G1-phase arrest. 
The setting of gates and the specifications for the size of cell cycle rely on the 
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experience of the experimentator. Further, the cells in S-phase of the cell cycle 
have varying amounts of DNA and hence may be falsely added to G1-phase or 
G2-/M-phase populations. Therefore, more profound analyses need to be added 
for consolidation of the results.  
The examinations, utilizing the reversible S-phase arrestor aphidicolin, reveal 
that tylophorine treatment of VSMC still allows slow S-phase progression in 
PDGF-BB treated cells and exclude an early S-phase arrest upon tylophorine 
treatment. In addition, consolidation that tylophorine is a G1-phase arrestor in 
PDGF-BB treated VSMC was gained by analyzing the phosphorylation status 
of the retinoblastoma protein. Tylophorine completely blocks its 
phosphorylation, which proves that tylophorine is a G1-phase-arrestor in 
PDGF-BB-activated rat aortic VSMC, which were mitogen-starved before 
stimulation.  
The outcome for calf-serum stimulated VSMC, which are not starved to 
quiescence seems to be different. The fact that tylophorine also inhibits the 
proliferation of cells ―cycling‖ in serum is irrevocable. But, our flow cytometry 
results do not give indications for a clear G1-phase arrest. It is possible that 
the S-phase population after 120 h in tylophorine-treated VSMC (Fig. 33) is 
due to an extreme slow-down of the cell cycle. However, a duplication of cells is 
not visible, even 120 h after mitogen stimulation. But another fact should be 
considered. VSMC are in different cell cycle phases at the moment of 
tylophorine treatment. It is therefore possible, that tylophorine blocks the cell 
cycle at the G1-/S-phase and the S-/G2-phase transition. This would explain 
why the cell cycle populations of G0/G1-phase and G2/M-phase are highly 
similar to the 0 h control level after 120 h. Just the cells which were in the 
early S-phase of the cell cycle contribute to the visible minor shift of the cell 
population from G1- to S-phase. Also the increase of mitochondrial mass and 
its DNA, which is also stained by PI, might contribute to this phenomenon.  
To track down the target of tylophorine which is responsible for the inhibition 
of proliferation in VSMC, we further analyzed the interaction of tylophorine 
with early PDGF-BB signaling pathways. The PDGF-BB stimulated 
proliferation of VSMC leads to activation of signaling molecules including the 
kinase Akt, the mitogen-activated protein (MAP)-kinases Erk 1/2 (p42/p44), 
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p38MAPK and c-Jun N-terminal kinase (JNK), and the transcription factor 
Signal transducer and activator of transcription 3 (Heldin CH et al., 1998; 
Andrae J et al., 2008). Western blot analyses demonstrated that tylophorine is 
not causing a G1-phase arrest via inhibition of these kinases or STAT3.  
There is also another possible signal transduction pathway in the cell, which 
might be responsible for the induction of proliferation. It is the NFκB signaling 
cascade. It was previously reported that tylophorine acts as an inhibitor of 
NFκB in HepG2, PANC-1, and CEM cells (Gao W et al., 2004). However, this 
report is using the (+)-S-tylophorine. Moreover, the role of the NFκB signaling 
for the PDGF-triggered proliferation of VSMC is controversial (Selzman CH et 
al., 1999; Erl W et al., 1999; Mehrhof FB et al., 2005). To examine potential 
activation of NFκB in our experimental setting, we investigated as a marker, 
the degradation of IκBα and observed that neither PDGF-BB is inducing 
degradation of IκBα, nor tylophorine has any effect on it. Taken together, we 
did not observe any influence of tylophorine on early PDGF-BB-induced 
signaling steps nor were changes of NFκB activation status detected at the 
level of IκBα. Our data furthermore support the notion that NFκB signaling 
pathways are not involved, at least, in PDGF-BB induced proliferation of 
VSMC.  
The progression through the cell cycle, activated by mitogenic stimuli like 
PDGF-BB, involves sequential activation of cyclin-dependent kinases (Cdks) 
and their regulatory subunits the cyclins (Vicente A, 2004). We revealed a 
massive degradation of cyclin D1 in PDGF-BB stimulated VSMC by 
tylophorine. The tylophorine induced down regulation of cyclin D1 can explain 
the observed G1-phase arrest, because cyclin D1 up regulation is necessary for 
the G1- to S-phase progression of the cell cycle. On the contrary, tylophorine 
treatment did not induce a degradation of cyclin A in VSMC as it was 
previously shown for cancer cells (Wu CM et al., 2009). We could demonstrate 
that the down regulation of cyclin D1 expression is occurring not just in PDGF-
BB but also in serum stimulated VSMC. Even in mitogen-starved quiescent 
VSMC, tylophorine is able to reduce cyclin D1 expression below basal levels. 
Therefore tylophorine inhibits the proliferation of VSMC independent of the 
Discussion    
 
106 
 
mitogenic stimuli as confirmed by the proliferation stop in PDGF- and CS-
stimulated VSMC. These findings lead to the conclusion that the proliferation 
of rat aortic VSMC is blocked by tylophorine via down regulation of cyclin D1 
and a subsequent G1-phase arrest in a stimulus-independent fashion, at least, 
in cell starved to quiescence prior to mitogen exposure.  Tylophorine leads to 
cyclin D1 degradation also in cycling unsynchronized VSMC. As mentioned 
above, the expected clear G1 arrest, however, does not occur. Instead, these 
cells seem to ―freeze‖ the cell cycle at the phase they are in, when they are 
exposed to tylophorine. There are no indications in the literature yet, whether 
such behavior can be explained by loss of cyclin D1. This issue needs attention 
in further investigations, as well as, the possible link between cyclin D1 
degradation and the putative increase in mitochondrial mass upon tylophorine 
treatment. Of note, proliferation has been linked to glycolysis (Warburg effect) 
(Vander Heiden MG et al., 2009). It is therefore conceivable that an inhibition 
of proliferation and glycolysis leads to a metabolic shift in the cell, which 
causes an increase in mitochondrial mass in these VSMC. We also observed a 
down regulation of p21, a known inhibitor of the cyclinD1-CDK4 complex 
(Levine AJ, 1997). Its up regulation is commonly accepted in many 
publications to indicate a cell cycle arrest in G1-/G0-phase (Abbas T and Dutta 
A, 2009). Association of p21 with cyclin D-CDK4/6 inhibits pRb 
phosphorylation and induces cell cycle arrest in G1-phase. Furthermore, p21 
mediates p53-dependent G1-phase growth arrest (Brugarolas J et al., 1995; 
Deng C et al., 1995). But p21 is also in low amounts required for normal cell 
cycle progression by stabilizing and promoting the active cyclin-CDK complex 
formation (Philipp J et al., 1999; LaBaer J et al., 1997; Besson A and Yong 
VW, 2000; Weiss RH et al., 2000). Thus tylophorine may induce a stop by 
interfering with the formation of an active cyclin D1/DCK4 complex by 
reducing both, cyclin D1 and p21 levels without altering CDK4 levels.  
This uncommon activity of tylophorine raised the questions for the mechanism 
of cyclin D1 and p21 down regulation. A decrease in protein levels of cyclin D1 
and p21 could be explained by decreased mRNA levels or an increased 
degradation of the protein. Here we demonstrate that tylophorine is not 
influencing cyclin D1 and p21 gene mRNA levels significantly, leading to the 
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conclusion that tylophorine is not influencing the transcription of these cell 
cycle regulators.  
Our experiments with chemical inhibition (MG132) of the proteasome 
machinery reveal, that tylophorine leads to down regulation of cyclin D1 via 
proteasomal pathways in rat aortic VSMC. This mechanism is so far not 
published for tylophorine or its analogues in other cell systems.  
We could also exclude species specific effects of tylophorine by testing the 
compound on HUVSMC. The anti-proliferative effect is reproducible, even with 
a highly similar IC50 of around 200 nM which can be observed in rat cells as 
well as cancer cells. Furthermore, the tylophorine-induced proteasome-
dependent degradation of cyclin D1 and p21 is also reproducable.  
Moreover, tylophorine is not just active in our cell culture models but also 
demonstrates high activity in a human saphenous vein model. Here, we 
demonstrate that tylophorine treatment prevents neointimal thickening.  
All the acquired results about the action of tylophorine point out a general 
mechanism which applies, at least, to rat and human smooth muscle cells. 
Maybe the mechanism is even conferrable to some cancer cell lines.  
The structural related tylophorine analogue DCB-3503 was reported to down 
regulate cyclin D1 in PANC-1 (Human pancreatic carcinoma, epithelial-like 
cell line) cells as well (Shiah HS et al., 2006). Furthermore, Wang Y et al. 
described a cyclin D1, p21, and p53 degradation for HepG2 (human 
hepatocellular cancer cell line) cells.  Although, the cyclin D1 down regulation 
is the same result as we describe it in our cell system, the additional findings 
differ. So far, our investigations of tylophorine do not indicate an influence on 
NFκB pathways or p53 degradation. Anyway, as described already by Gao W 
and colleagues in 2007, the structural relation between the tylophora alkaloids 
does not necessarily argue for the same mechanism in the cells.  
The unbiased kinase array approach to detect possible targets of tylophorine in 
SMC could not be reproduced with our cell-based data. The phosphorylation 
site serine 9 of p53 was not 43-fold upregulated by tylophorine treatment in 
VSMC as predicted from the assay. The phosphorylation of p53 on the serine 9 
position would have suggested that tylophorine induces DNA damage in the 
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cell (Higashimoto Y et al., 2000). Recent literature introducing FBXO31 up 
regulation as part of a fast degradation pathway for cyclin D1 after DNA 
damage could have supported the idea of tylophorine as a DNA damaging 
compound and explained the observed cyclin D1 degradation (Santra MK et 
al., 2009). But our experiments did not end up in satisfying and consistent 
results for FBXO31 (data not shown). With our result for the p53 serine 9 
phosphorylation site, namely no highly upregulation upon tylophorine 
treatment, we can substantiate that tylophorine is no DNA damaging agent. In 
this context we also investigated other phosphorylation sites of p53 in the 
presence of tylophorine. The lack of influence on p53 phosphorylation site 
serine 46 is further another argument against an induction of apoptosis by 
tylophorine and corroborates our findings of the Annexin V staining assay. 
According to literature (Mayo LD et al., 2005) this serine phosphorylation site 
is highly upregulated after induction of apoptosis. Similar indications can be 
obtained by the investigations of the p53 phosphorylation on serine 15. Our 
results even show a dephosphorylation by tylophorine on the serine 15 site. 
According to literature, this dephosphorylation could promote cell survival (Li 
DW et al., 2006). 
How tylophorine induces proteasome-mediated cyclin D1 and p21 degradation 
is still unclear. For the cyclin D1 turnover exist, besides DNA damage induced 
degradation, several possibilities.  
First, cyclin D1 degradation is dependent on threonine 286 (T286) 
phosphorylation and regulated by ubiquitin-dependent proteasomal 
degradation (Diehl et al., 1997). Glycogen synthase kinase 3β (GSK3β) is 
capable of phosphorylating cyclin D1 on T286 and inducing its rapid turnover 
(Diehl JA et al., 1998). Our data does not support an increased 
phosphorylation of cyclin D1 after tylophorine treatment, at least, for 15 min 
to 90 min after tylophorine incubation. Immunoblots for shorter tylophorine 
incubation times did not give conclusive results. Therefore, an up regulation of 
the phosphorylation on T286 cannot be excluded.  
It was also reported, that cyclin D1 degradation occurs independently of 
GSK3β. A protein kinase Mirk/Dyrk1b seems to be also responsible for the 
regulation of cyclin D1 stability (Zou Y et al., 2004). It is active at G0 and early 
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G1 phases of the cell cycle and phosphorylates cyclin D1 on T288. The data 
published about the phosphorylation site T288 on cyclin D1 is arguable.  So far 
there is no antibody against this phosphorylation site commercially available. 
Antibodies used in publications are self-made or the provider was not specified. 
Therefore, the phosphorylation site T288 was not evaluated in our studies. 
Furthermore, it was demonstrated that various chemically-induced or 
environmental stresses induce cyclin D1 degradation in cancer cells via the 
p38SAPK2 pathway (Casanovas et al., 2007). The results we obtained for 
phospho-p38 during the evaluation of the early PDGF signaling indicate that 
this pathway is not influenced by tylophorine.  
A cyclin D1 splice variant, cyclin D1b, has also been reported (Betticher DC et 
al., 1995; Hosokawa Y et al., 1997; Lu F et al., 2003). It lacks a C-terminal 
domain where the T286 residue is located. This loss of the regulatory region 
does not significantly increase the half-life of cyclin D1b. It is constitutively 
nuclear and has been shown to be a poor activator of CDK4 and RB 
phosphorylation (Solomon DA et al., 2003). Our antibodies do not discriminate 
between the two cyclin D1 variants, because they target the amino-acid 
residues 151 – 170 of a conserved domain. Tthe almost complete degradation of 
cyclin D1 points out that even this splice-variant gets degraded after 
tylophorine treatment of the cells.  
Second, not just the phosphorylation of cyclin D1 but its ubiquitinylation could 
also be modulated by tylophorine. The F-box proteins FBX4 and FBXW8 are, 
besides FBXO31, mediators of cyclin D1 ubiquitinylation (Lin DI et al., 2006; 
Okabe H et al., 2006). FBX4 recognition of cyclin D1 requires the presence of 
αB crystalline and the phosphorylation of T286. Both FBX4 and αB crystalline 
are required for the rapid ubiquitin-dependent degradation of T286 
phosphorylated cyclin D1 (Lin DI et al., 2006). Also FBXW8 mediates cyclin D1 
ubiquitinylation after T286 phosphorylation (Okabe H et al., 2006). All these 
ubiquitinylations are elements for further investigations. 
The literature about the degradation of p21 is scarce. p21 is also found to be 
degraded in an ubiquitin-independent manner by the proteasome (Chen X et 
al., 2004; Sheaff RJ et al., 2000). It can be phosphorylated at serine 130 by 
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CDK2. There is also a p21 turnover independent of ubiquitin E3 ligase 
activity. It is promoted by Mdm2 (Zhang Z et al., 2004; Jin Y et al. 2003). The 
exact influence of tylophorine on these pathways cannot be specified so far.  
Investigations of the tylophorine analogue DC-3503 point out, that tylophorine 
reduction might be due to modulation of translational processes (Wang Y et al. 
2010). Our data do not exclude this option for tylophorine in VSMC and 
HUVSMC. The fact that proteasomal inhibition blocks the tylophorine induced 
cyclin D1 and p21 down regulation just substantiates that tylophorine acts via 
these degradatory pathways. The reduction of cyclin D1 translation, combined 
with a short half-life of around 21 min could, still further contributes to the 
fast down regulation by tylophorine. The specific and detailed mechanism of 
tylophorine induced cyclin D1 and p21 degradation still needs to be 
determined.  
Taken together, we found that tylophorine, a phenanthroindolizidine alkaloid 
isolated from Tylophora indica (Asclepiadaceae), is able to inhibit proliferation 
of rat aortic vascular smooth muscle cells and human umbilical vein smooth 
muscle cells by down regulation of cyclin D1 through a proteasome-dependent 
pathway. Furthermore, we demonstrate that tylophorine treatment prevents 
neointimal thickening in human saphenous veins.  
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5.2. Peucedanum ostruthium and its major coumarins 
 
In the next part of the study, we examined the rhizome extract of Peucedanum 
ostruthium, for its putative anti-proliferative activity in rat aortic VSMC.  
Peucedanum ostruthium, a traditionally used medicinal plant with anti-
inflammatory properties, was a hit of a screening of plant extracts. The 
Dichloromethane (DCM)-extract of Peucedanum ostruthium was therefore 
interesting for further evaluation.  
To find the components responsible for the activity of this extract, we 
performed a fractionation followed by isolation of the pure compounds 
(extraction and isolation performed by Mag. Silvia Vogl, University of Vienna). 
The isolation of all components of this extract was not possible, but we gained 
the 7 major coumarins.  It has been documented that coumarins are major 
bioactive constituents of extracts from Peucedanum ostruthium roots 
(Hiermann A and Schantl D, 1998; Hiermann A et al., 1996). The anti-
proliferative activity of these compounds was tested and resulted in one main 
active substance of the extract – the coumarin ostruthin. Anti-proliferative 
action of ostruthin in VSMC was never investigated before, however one study 
examined the inhibitory action of the structurally similar osthole isolated from 
Angelica pubescens in the smooth muscle cell line A10 (Guh JH et al., 1996). 
Contradictory to this finding, we did not observe a potent inhibitory action of 
osthole in our model system utilizing primary rat aorta VSMC. Although, all 
the substances show structural similarity, just ostruthin was able to inhibit 
the proliferation of VSMC significantly. Since also the structurally similar 
linear furanocoumarins have no effect on the proliferation of VSMC, it can be 
concluded that the prenylgroup in R3-position is necessary for the inhibitory 
effect (See table 2).  Furthermore, ostruthin constitutes around 32% of the 
total amount of the extract, and it can be recalculated that the 24 µg/mL from 
the extract (the IC50 exhibited from the extract is 24 ± 14 µg/mL) contains 
approximately 26 µM ostruthin. Since ostruthin inhibited VSMC proliferation 
with IC50 of 11.07 ± 2.23 µM, its activity can entirely explain the inhibitory 
properties of the DCM extract. Thus, we describe a new bioactivity of 
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Peucedanum ostruthium and identify ostruthin as major responsible 
compound.  
The mechanism behind ostruthins action on VSMC still remains an unsolved 
question. First of all, it will be necessary to exclude the induction of apoptosis 
by ostruthin treatment in VSMC. If ostruthin is not inducing cell death, the 
specific target of ostruthin in the cell needs to be clarified. Therefore, the 
ostruthin-induced cell cycle arrest needs to be analyzed by investigation of 
cyclin and CDK levels or their inhibitors.  
In the end, it could be evaluated if ostruthin inhibits the proliferation of 
endothelial cells to a less extent than VSMC. Then, it could be a promising 
promising lead for the treatment of vasculo-proliferative disorders, such as 
restenosis. 
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7. Appendix 
7.1. Abbreviations 
 
A 
Akt  Protein kinase B 
 
B 
BSA  Bovine serum albumin 
BMS Bare metal stents 
  
C 
CABG Coronary artery bypass grafting 
CDK Cyclin dependent kinase 
cDNA  Complementary DNA 
CKI Cyclin dependent kinase inhibitor 
CS  Calf serum 
CVD Cardiovascular disease 
 
D 
DCM Dichloromethane  
ddH2O  Double distilled water 
DEPC Diethylpyrocarbonate 
DES Drug eluting stents 
DMEM  Dulbecco‘s modified Eagle‘s medium 
DMSO  Dimethyl sulfoxide 
DNA  Desoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
DTT  Dithiothreitol 
 
E 
EC Endothelial cells 
ECL  Enhanced chemiluminescence 
EDTA  Ethylenediamintetraacetic acid 
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ERK  Extracellular signal-regulated kinase 
 
F 
FACS  Fluorescence-activated cell sorter 
FITC  Fluorescein isothiocyanate 
FBXO31 F-box only protein 31   
FBX4 F-box only protein 4   
 
G 
GFP Green fluosrescence protein 
GSK-3β  Glycogen synthase kinase 3 β 
GPCRs G protein-coupled receptors  
 
H 
HBSS  Hank‘s balanced salt solution 
HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)- 
 ethansulfonsäure 
HUVSMC Human umbilical vein smooth muscle cells 
 
I 
IκBα NF-kappa-B inhibitor alpha 
 
J 
JNK  c-Jun N-terminal kinase 
 
K 
kDA  kilo Dalton 
 
L 
LDL Low density lipoprotein 
 
M 
MAPK Mitogen activated protein kinase 
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mc  Monoclonal 
MG132 Z-Leu-Leu-Leu-aldehyde 
mRNA  Messenger RNA 
mTOR Mammalian target of rapamycin 
 
N 
NFκB  Nuclear factor- κB 
 
P 
PAA  Polyacrylamide 
PBS  Phosphate buffered saline 
Pc Polyclonal 
PCR  Polymerase chain reaction 
PDGF Plateled-derived growth factor 
PI3K  Phosphatidylinositol 3-kinase 
PMSF  Phenylmethylsulphonylfl uoride 
PTCA percutaneous transluminal coronary 
 angioplasty 
PVDF  Polyvinylidenedifl uoride 
 
Q 
qPCR  Quantitative real-time PCR 
 
R 
RNA  Ribonucleic acid 
RT  Reverse transcription 
RTKs Receptor tyrosine kinases 
RT-PCR  Real time PCR 
 
S 
SDS  Sodium dodecyl sulphate 
SDS-PAGE  Sodim dodecyl sulphate polyacrylamide gel 
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 electrophoresis 
SMCs Smooth muscle cells 
 
T 
TBS-T   Tris-buffered saline containing Tween 20 
TEMED  N,N,N´,N´-tetramethylethylene diamine 
 
U 
U  Units 
 
V 
VSMC  Vascular smooth muscle cells 
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7.2. Supplementary data 
 
7.2.1. Pepscan results 
PROTEIN PSITE Upstream kinase 
Fold 
activatio
n 
p53 S9 
ATM + 
Casein_kinase_1,_alpha_1 
43.70 
SMAD5 Y128 nd 3.57 
STAT5B Y679 c-Src 2.35 
Metabotropic 
glutamate receptor 1 
T695 Protein_kinase_C_alpha 2.09 
Erythropoietin 
receptor 
Y368 Janus_kinase_2 2.08 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 2 
T475 Protein_kinase_C_alpha 1.87 
p47-phox S348 
Casein_kinase_II,_alpha_2 + 
Casein_kinase_II,_beta 
1.78 
RGS2 S46 
Protein_kinase__cGMP-
dependent_type_I 
1.78 
SPIB transcription 
factor 
S146 
Casein_kinase_II,_alpha_1 + 
Casein_kinase_II,_alpha_2 
1.77 
Regulator of G 
protein signaling 19 
S151 ERK2 1.72 
Synuclein alpha Y136 SYK 1.62 
Transcription factor 
IIA, 1 
S280 
Casein_kinase_II,_alpha_2 + 
Transcription_factor_IID 
1.62 
Stomatin S10 - 1.59 
Formyl peptide 
receptor 1 
S328 
G_protein_dependent_receptor_k
inase_2 
1.56 
AFX 1 S196 AKT1 1.56 
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HLA-A S359 Protein_kinase_C_alpha 1.55 
Polo like kinase T210 - 1.55 
FAS associated factor 
1 
S289 Casein_kinase_II,_alpha_1 1.53 
CTD phosphatase, 
subunit 1 
S575 
Casein_kinase_II,_alpha_2 + 
Casein_kinase_II,_beta 
1.48 
TBK1 S172 - 1.45 
ERK5 T218 - 1.42 
Protein phosphatase 
inhibitor 2 
S87 
Casein_kinase_II,_alpha_1 + 
Casein_kinase_II,_alpha_2 
1.42 
E2F transcription 
factor 1 
S403 
Cyclin_dependent_kinase_7 + 
TFIIH_62_kDa_subunit 
1.42 
ZAP70 Y319 ZAP70 1.41 
Syntrophin alpha 1 S193 MAPK12 1.39 
Ribosomal S6 kinase 
1 
S230 
3_Phosphoinositide_dependent_p
rotein_kinase_1 + 
Pyruvate_dehydrogenase_kinase
,_isoenzyme_1 
1.37 
Phosphatidylinositol 
3-kinase, regulatory 
gamma subunit 
Y341 - 1.35 
Eukaryotic 
translation initiation 
factor 4E 
S209 
Protein_kinase_C,_beta_1 + 
Protein_kinase_C,_gamma 
1.34 
p21-activated kinase 
7 
S573 p21_activated_kinase_7 1.33 
LNK Y273 Lck + ZAP70 1.33 
SHP2 S591 
Protein_kinase_C,_beta_1 + 
Protein_kinase_C,_eta 
1.31 
Table 1. Pepscan results. Depicted are protein and their phosphorylation site (PSITE) as well 
as the upstream regulatory kinase. The fold activation is demonstrating the upregulation of 
phosphorylation by tylophorine and PDGF-BB treatment of VSMC compared to DMSO and 
PDGF-BB treated cells. 
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7.2.2. Chemical structures of coumarins 
 
Simple coumarins 
 
 
 
 
 
 
 R1 R2 R3 
coumarin H H H 
umbelliferone H OH H 
scopoletin H OH OMe 
osthole 
 
OMe H 
auraptene H 
O
 
H 
ostruthin H OH 
 
O OR2
R3
R1
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Linear furanocoumarins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 R1 R2 
bergaptol H OH 
bergapten H OMe 
isopimpinellin OMe OMe 
isoimperatorin H 
O
 
imperatorin 
O
 
H 
heraclenin 
O
O
 
H 
oxypeucedanin H 
O
O
 
bergamottin H 
O
 
ostruthol H 
O
O
OH
O
 
OO O
R1
R2
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Angular furanocoumarins  
  
 
 
 
 
Table 3. Structural classification of all tested coumarins 
 
 
 
 
 
 
 
 
 
 
 
 
 R1 R2 
isobergapten H OMe 
O OO
R2
R1
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